Programme at a Glance - Geyseco.es
Programme at a Glance - Geyseco.es
Programme at a Glance - Geyseco.es
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
22nd<br />
INTERNATIONAL CONGRESS ON THROMBOSIS<br />
www.medleague-thrombosis.org<br />
FINAL PROGRAMME<br />
NICE Acropolis<br />
FRANCE 6-9 October 2012<br />
www.thrombosis2012.org
Committe<strong>es</strong><br />
CONGRESS EXECUTIVE COMMITTEE<br />
Pr<strong>es</strong>ident<br />
Jean-François Schved (Montpellier, France)<br />
Vice-Pr<strong>es</strong>ident<br />
Jacqueline Conard (Paris, France)<br />
Ismaïl Elalamy (Paris, France)<br />
Françoise Dign<strong>at</strong>-George (Marseille, France)<br />
Emile Ferrari (Nice, France)<br />
Thomas Lecompte (Nancy, France)<br />
P<strong>at</strong>rick Mismetti (Saint-Etienne, France)<br />
Isabelle Quéré (Montpellier, France)<br />
Christine Biron-Andréani (Montpellier, France)<br />
Honorary Pr<strong>es</strong>ident<br />
Meyer-Michel Samama (Paris, France)<br />
COUNCIL OF THE MEDITERRANEAN<br />
LEAGUE AGAINST THROMBOEMBOLIC<br />
DISEASES· EXECUTIVE BOARD<br />
Pr<strong>es</strong>ident<br />
Pier M. Mannucci<br />
Past Pr<strong>es</strong>ident<br />
Christos Liapis<br />
General Secretary<br />
Maria Ter<strong>es</strong>a Santos<br />
Members<br />
Meyer-Michel Samama<br />
Jacqueline Conard<br />
Paolo Prandoni<br />
David Varon<br />
COUNTRY COUNCILLORS<br />
I.B. Topalov (Bulgaria)<br />
Ana Bronic (Cro<strong>at</strong>ia)<br />
Andrew Nicolaid<strong>es</strong> (Cyprus)<br />
Nevine Kassim (Egypt)<br />
Jacqueline Conard (France)<br />
Ismaïl Elalamy (France)<br />
Antonios H<strong>at</strong>zizacharias (Greece)<br />
Anthi Travlou (Greece)<br />
Uri Seligsohn (Israel)<br />
David Varon (Israel)<br />
Maria Benedetta Don<strong>at</strong>i (Italy)<br />
Paolo Prandoni (Italy)<br />
Ali Taher (Lebanon)<br />
Cherif Abdelkhirane (Morocco)<br />
Zoubida Tazi (Morocco)<br />
Manuel Campos (Portugal)<br />
Luis Manuel Cunha-Ribeiro (Portugal)<br />
Abdul Kareem Al Momen (Saudi Arabia)<br />
Ivo Elezovic (Serbia)<br />
Mojca Stegnar (Slovenia)<br />
Amparo Estellés (Spain)<br />
Maria Ter<strong>es</strong>a Santos (Spain)<br />
Lina Badimon (Spain)<br />
Sami Guermazi (Tunisia)<br />
Turgut Ulutin (Turkey)<br />
Mehmet Nej<strong>at</strong> Akar (Turkey)<br />
Speakers<br />
Walter Ageno<br />
University of Insubria, Clinical and experimental<br />
Medicine Department. Var<strong>es</strong>e, Italy<br />
Pierre Albaladejo<br />
Grenoble, France<br />
Juan Ignacio Arcelus Martínez<br />
Universidad de Granada, Surgery Department. Granada,<br />
Spain<br />
Jean-François Arnal<br />
CHU, Faculté Médicine et Université de Toulouse III.<br />
Paris, France<br />
Lina Badimon<br />
Cardiovascular R<strong>es</strong>earch Center, CSIC-ICCC. Barcelona,<br />
Spain<br />
Ángel<strong>es</strong> Blanco Molina<br />
Hospital Reina Sofía, Internal Medicine Department.<br />
Córdoba, Spain<br />
Chantal M. Boulanger<br />
Paris Cardiovascular R<strong>es</strong>earch Center, Inserm UMR970.<br />
Paris, France<br />
Marie-Germaine Bousser<br />
Hôpital LARIBOISIERE. Neurology Department. Paris,<br />
France<br />
Margareth Castro Ozelo<br />
University of Campinas (UNICAMP), Hem<strong>at</strong>ology<br />
Department (Hemocentro UNICAMP). Campinas, Brazil<br />
Marco C<strong>at</strong>taneo<br />
Università degli Studi di Milano, Dipartimento della<br />
Salute. Milano, Italy<br />
Jacqu<strong>es</strong> Chiaroni<br />
Marseille, France<br />
Ariel Cohen<br />
Paris, France<br />
Jean-Philippe Collet<br />
Groupe Hospitalier Pitié-Salpetrierè. Paris, France<br />
Francis Couturaud<br />
Cavale Blanche Hospital. Internal Medicine and Ch<strong>es</strong>t<br />
Diseas<strong>es</strong> Department. Br<strong>es</strong>t, France<br />
Ola E. Dahl<br />
Thrombosis R<strong>es</strong>earch Institute. London, UK.<br />
Bas de La<strong>at</strong><br />
Biochemitry, CARIM. Maastricht, The Netherlands<br />
K<strong>at</strong>rien Devre<strong>es</strong>e<br />
Gent University Hospital. Coagul<strong>at</strong>ion Labor<strong>at</strong>ory<br />
Department. Ghent, Belgium<br />
Christophe Dubois<br />
Faculty of Medicine La Timone. Marseille, France<br />
Charl<strong>es</strong> T. Esmon<br />
Howard Hugh<strong>es</strong> Medical Institute/ Oklahoma Medical<br />
R<strong>es</strong>earch Found<strong>at</strong>ion, Coagul<strong>at</strong>ion Biology Labor<strong>at</strong>ory.<br />
Oklahoma, USA<br />
Anna Falanga<br />
Ospedali Riuniti of Bergamo, Inmmunohem<strong>at</strong>ology and<br />
Trasfusion Medicine Department. Bergamo, Italy<br />
Pierre Fontana<br />
University Hospital Geneva. Angiology and Haemostasis<br />
Department. Geneva, Switzerland<br />
Bruce Furie<br />
Harvard Medical School. Harvard, USA<br />
Muriel Giansily-Blaizot<br />
CHU of Montpellier (Hôpital Saint Eloi), Hém<strong>at</strong>ologie<br />
Biologique Department. Montpellier, France<br />
Augustin Hellmut<br />
German Cancer R<strong>es</strong>earch Center, Vascular Oncology and<br />
Metastasis R<strong>es</strong>earch Department. Heidelberg, Germany<br />
Cedric Hermans<br />
Cliniqu<strong>es</strong> Universitair<strong>es</strong> Saint-Luc. Division of<br />
Haem<strong>at</strong>ology. Bruxell<strong>es</strong>, Belgium<br />
Jean Pierre Laroche<br />
CHU Montpellier, Vascular Medicine Department.<br />
Montpellier, France<br />
Grégoire Le Gal<br />
CHRU de la Cavale Blanche, Département de medicine<br />
interne et de pneumologie. Ottawa, Canada<br />
Jean-Yv<strong>es</strong> Le Heuzey<br />
Hôpital Européen Georg<strong>es</strong> Pompidou, Cardiologie et<br />
Rythmologie. Paris, France<br />
Thomas Lecompte<br />
CHU de Nancy-Hospital de Brabois Service d’Hámtologie<br />
Biologique. Nancy, France<br />
Xavier Leleu<br />
Service d<strong>es</strong> maladi<strong>es</strong> du sang, Hopital Huriez. Lille,<br />
France<br />
Mario Mandala<br />
Department of Oncology and Haem<strong>at</strong>ology. Ospedali<br />
Riuniti Bergamo, Italy<br />
P<strong>at</strong>rick Mismetti<br />
Saint-Etienne, France<br />
Rienk Nieuwland<br />
Academic Medical Centre of the University of<br />
Amsterdam. Clinical Chemistry Department . Amsterdam,<br />
The Netherlands<br />
Mette Nørgaard<br />
Aarhus University Hospital, Clinical Epidemiology<br />
Department, Aarhus, Denmark<br />
Vittorio Pengo<br />
Clinica Cardiologica, Centro Trombosi. Dipartmento di<br />
Scienze Cardiologiche Toraciche e Vascolari.Università<br />
degli Studi di Padova, Italy<br />
Geneviève Plu-Bureau<br />
Paris, France<br />
Thomas Renné<br />
Karolinska Institute and Universitz Hospital, Molecular<br />
Medicine and Surgerz Department. Stockholm, Sweden<br />
Wolfram Ruf<br />
The Scripps R<strong>es</strong>earch Institute. Immunology and<br />
Microbial Science Department. La Jolla, U.S.A.<br />
Charl<strong>es</strong> Marc Samama<br />
Cochin University Hospital. Ana<strong>es</strong>th<strong>es</strong>ia and Intensive<br />
care Department. Paris, France<br />
Meyer Michel Samama<br />
BIOMNIS LABORATORIES, R&D Department. Ivry, France<br />
Stephanie Schultz<br />
Cardiology,German Heart Center Munich, Germany<br />
Jean-Sébastien Silv<strong>es</strong>tre<br />
Inserm U970, Paris Cardiovascular R<strong>es</strong>earch Center.<br />
Paris, France<br />
Regine Sitruk-Ware<br />
Popul<strong>at</strong>ion Council, Center for Biomedical R<strong>es</strong>earch.<br />
New York, USA<br />
Armando Tripodi<br />
University of Milano, Internal Medicine Department.<br />
Milano, Italy<br />
David Varon<br />
Hadassah-Hebrew University Medical Center,<br />
Hem<strong>at</strong>ology Department. Jerusalem, Israel
Chairmen<br />
Ulrich Abildgaard<br />
Oslo University Hospital.<br />
Oslo, Norway<br />
Essam AboelNazar<br />
UmQ University.<br />
Jeddah, Saudi Arabia<br />
An<strong>at</strong> Aharon<br />
Rambam Health Care Campus. Haifa, Israel<br />
Nej<strong>at</strong> Akar<br />
TOBB-ETU Hospital.<br />
Ankara, Turkey<br />
Abdulkareem Almomen<br />
College of Medicine & KKUH, King Saud University.<br />
Riyadh, Saudi Arabia<br />
Ana Bronic<br />
Traum<strong>at</strong>ology Clinic, Clinical Hospital Centre ´S<strong>es</strong>tre<br />
Milosrdnice´. Zagreb, Cro<strong>at</strong>ia<br />
Sergio Coccheri<br />
University of Bologna, Italy<br />
Jacqueline Conard<br />
Hotel-Dieu. Paris, France<br />
Ola E. Dahl<br />
Innlandet Hospital Trust and Thrombosis R<strong>es</strong>earch<br />
Institute. Kolsås, Norway<br />
Hervé Decousus<br />
Centre d’Inv<strong>es</strong>tig<strong>at</strong>ion Clinique CIE3 (INSERM/DHOS).<br />
Hôpital Nord CHU ST ETIENNE. Saint-Étienne, France<br />
Franc<strong>es</strong>co Dentali<br />
Insubria University, Var<strong>es</strong>e, Italy<br />
Françoise Dign<strong>at</strong>-George<br />
INSERM UMR 608, UFR de Pharmacie,<br />
Campus Timone Marseille, France<br />
Maria Benedetta Don<strong>at</strong>i<br />
Fondazione di Ricerca e Cura “Giovanni Paolo II”<br />
CAMPOBASSO, Italy<br />
Sabine Eichinger<br />
Medical University of Vienna<br />
Austria, Viena<br />
Ismaïl Elalamy<br />
Hôpitaux Universitair<strong>es</strong> Paris-Est. Breullet, France<br />
Ginés Escolar<br />
Hospital Clinic. Barcelona, Spain<br />
Charl<strong>es</strong> T. Esmon<br />
Howard Hugh<strong>es</strong> Medical Institute/ Oklahoma Medical<br />
R<strong>es</strong>earch Found<strong>at</strong>ion, Coagul<strong>at</strong>ion Biology Labor<strong>at</strong>ory.<br />
Oklahoma, USA.<br />
Amparo Estell<strong>es</strong><br />
Centro de Inv<strong>es</strong>tigación Hospital Universitario La Fe<br />
Valencia, Spain<br />
Anne Marie Fischer<br />
Labor<strong>at</strong>oire d’hém<strong>at</strong>ologie.<br />
Hôpital Européen Georg<strong>es</strong> POMPIDOU. Paris, France<br />
Denis Gerard Wahl<br />
Lorraine University. Nancy, France<br />
Grigoris Gerotziafas<br />
Hôpitaux Universitair<strong>es</strong> Est Parisien, Assistance Publique<br />
Hôpitaux de Paris. Faculté de médecine Pierre et Marie<br />
Curie, Université Paris VI. Paris, France<br />
Emna Gouider<br />
Tunisia<br />
Isabelle Gouin-Thibault<br />
Université Paris D<strong>es</strong>cart<strong>es</strong>.<br />
Paris, France<br />
Sami Guermazi<br />
Hôpital Charl<strong>es</strong> Nicolle de Tunis, Tunisia<br />
Job Harenberg<br />
Clinical Pharmacology, Medical Faculty Mannheim,<br />
University of Heidelberg Mannheim, Germany<br />
Nevine Kassim<br />
Ain Shams University, Faculty of Medicine.<br />
Heliopolis, Cairo. Egypt<br />
Silvy Laporte<br />
MCU-PH Pharmacologie Clinique, Hôpital Nord.<br />
Université Jean-Monnet. Saint-Etienne, France<br />
Thomas Lecompte<br />
Hopitaux Universitair<strong>es</strong> de Geneve.<br />
Nancy, France<br />
Pier M. Mannucci<br />
IRCCS Ca’ Granda Maggiore Policlinico Hospital<br />
Found<strong>at</strong>ion. Milan, Italy<br />
P<strong>at</strong>rick Mismetti<br />
Hôpital Nord. Saint-Etienne, France<br />
Pierre-Emmanuel Morange<br />
INSERM, UMR_S 626, Université de la Méditerranée,<br />
CHU Timone. Marseille, France<br />
Paolo Prandoni<br />
Clinica Medica 2, University of Padova, Italy<br />
Meyer Michel Samama<br />
BIOMNIS LABORATORIES.<br />
Ivry-Sur-Seine Cedex, France<br />
Charl<strong>es</strong> Marc Samama<br />
Cochin University Hospital.<br />
París, France<br />
Per Morten Sandset<br />
Oslo University Hospital Rikshospitalet.<br />
Oslo, Norway<br />
Maria Ter<strong>es</strong>a Santos<br />
University Hospital La Fe.<br />
Valencia, Spain<br />
Uri Seligsohn<br />
Chaim Sheba Medical Center.<br />
Tel Hashomer, Israel<br />
Virginie Siguret Depasse<br />
MCU-PH, Hôpital Européen Georg<strong>es</strong> Pompidou.<br />
Paris, France<br />
Mojca Stegnar<br />
Ljubljana, Slovenia<br />
Pierre Toulon<br />
France<br />
Anthi Travlou<br />
Athens, Greece<br />
Armando Tripodi<br />
University of Milano.<br />
Milan, Italy<br />
Turgut Ulutin<br />
Cerrahpasa Medical Faculty.<br />
Instanbul, Turkey<br />
Juana Vallés<br />
Hospital La Fe.<br />
Valencia, Spain<br />
David Varon<br />
Hadassah-Hebrew University Medical Center.<br />
Jerusalem, Israel.<br />
Tazi Mezalek Zoubida<br />
Ibn Sina Hospital.<br />
Rab<strong>at</strong>, Morocco
Acknowledgements<br />
On behalf of the Mediterranean League against Thromboembolic Diseas<strong>es</strong> (MLTD), we take gre<strong>at</strong> pleasure<br />
in inviting you to <strong>at</strong>tend the 22nd Intern<strong>at</strong>ional Congr<strong>es</strong>s on Thrombosis in Nice (October 6-9, 2012).<br />
Nice has been chosen for the venue of this meeting because of its loc<strong>at</strong>ion on the Mediterranean Sea,<br />
its dynamic university and its acc<strong>es</strong>sibility. The Congr<strong>es</strong>s Centre, Acropolis, is an <strong>at</strong>tractive place in<br />
downtown Nice with a modern and functional structure.<br />
The most important is the program of the s<strong>es</strong>sions, combining both clinical and biological aspects of<br />
thrombosis which is the aim of MLTD congr<strong>es</strong>s<strong>es</strong>. We have planned plenary s<strong>es</strong>sions, symposia and<br />
educ<strong>at</strong>ional s<strong>es</strong>sions on up-to-d<strong>at</strong>e subjects, all pr<strong>es</strong>ented by outstanding lecturers. In addition, we trust<br />
on your willing to send abstracts on original new findings.<br />
New antithrombotics, antipl<strong>at</strong>elet agents and anticoagulants, are now available. Their mode of action,<br />
indic<strong>at</strong>ions, dos<strong>es</strong> and side-effects need to be clarified, as well as their influence on labor<strong>at</strong>ory t<strong>es</strong>ts.<br />
In 2012, the importance of ‘old’ antithrombotics such as aspirin, clopidogrel, vitamin K antagonists and<br />
heparins shall be considered. The guidelin<strong>es</strong> have been published in different countri<strong>es</strong> for a tre<strong>at</strong>ment<br />
and prevention of thrombosis: they must be known and followed by clinicians in the real life.<br />
New approach<strong>es</strong> based on cellular interactions, proteomics and genomics will be pr<strong>es</strong>ented and discussed.<br />
Women’s Health also is a major topic. Pregnancy, hormonal tre<strong>at</strong>ments for contraception, menopause<br />
and breast cancer can increase the risk of thrombosis, and the most recent area impacts all assisted<br />
reproductive technologi<strong>es</strong>. Other innov<strong>at</strong>ive them<strong>es</strong> on the l<strong>at</strong><strong>es</strong>t r<strong>es</strong>earch will be developed.<br />
We hope many of you will <strong>at</strong>tend this congr<strong>es</strong>s and we look forward to welcoming you for a very ‘Nice’<br />
meeting.<br />
Pr<strong>es</strong>ident<br />
Jean-François Schved<br />
Vice-Pr<strong>es</strong>ident<br />
Jacqueline Conard
General inform<strong>at</strong>ion<br />
VENUE<br />
Nice Acropolis (Palais d<strong>es</strong> Congrès)<br />
1, Esplanade Kennedy - BP 4083<br />
06302 Nice Cedex 4, France<br />
CONTINUING MEDICAL EDUCATION<br />
This programme is accredited by the European Board for<br />
Accredit<strong>at</strong>ion in Cardiology (EBAC) for 15 hours of external<br />
CME credits. Each participant should claim only those hours<br />
of credit th<strong>at</strong> have actually been spent in the educ<strong>at</strong>ional<br />
activity. EBAC works according to the quality standards of<br />
the European Accredit<strong>at</strong>ion Council for Continuing Medical<br />
Educ<strong>at</strong>ion (EACCME), which is an institution of the European<br />
Union of Medical Specialists (UEMS).<br />
In compliance with EBAC/ EACCME guidelin<strong>es</strong>, all speakers/ chairpersons particip<strong>at</strong>ing<br />
in this programme have disclosed or indic<strong>at</strong>ed potential conflicts of<br />
inter<strong>es</strong>t, which might cause a bias in the pr<strong>es</strong>ent<strong>at</strong>ions. The Organizing Committee/Course<br />
Director is r<strong>es</strong>ponsible for ensuring th<strong>at</strong> all potential conflicts<br />
of inter<strong>es</strong>t relevant to the event are declared to the audience prior to the CME<br />
activiti<strong>es</strong>.<br />
BADGE<br />
Each participant will receive a name badge upon check-in <strong>at</strong> the Registr<strong>at</strong>ion<br />
D<strong>es</strong>k. The badge will be considered as an official meeting document and should<br />
be carried all the time in order to get granted acc<strong>es</strong>s to the meeting rooms.<br />
GALA DINNER<br />
The Gala Dinner will take place on Hotel Palais de la Mediterranée 13,<br />
promenade d<strong>es</strong> Anglais, 06011 Nice<br />
To <strong>at</strong>tend the gala dinner, do not forget to bring your ticket or invit<strong>at</strong>ion. Without<br />
it, the acc<strong>es</strong>s to the r<strong>es</strong>taurant will be denied.<br />
The Gala Dinner will start <strong>at</strong> 20:30 hs. We kindly ask all participants for being<br />
on time.<br />
REGISTRATION DESK<br />
The registr<strong>at</strong>ion d<strong>es</strong>k is loc<strong>at</strong>ed in the Main Hall in front of the entrance and it<br />
will be open on:<br />
S<strong>at</strong>urday October 6th 12:00 - 18:30<br />
Sunday October 7th 07:30 - 18:30<br />
Monday October 8th 07:30 - 18:30<br />
Tu<strong>es</strong>day October 9th 08:00 - 15:30<br />
PREVIEW ROOM<br />
The preview room is loc<strong>at</strong>ed on the Herm<strong>es</strong> Foyer near the Herm<strong>es</strong> Auditorium.<br />
All speakers should check and deliver their PowerPoint pr<strong>es</strong>ent<strong>at</strong>ions to the<br />
Preview Room <strong>at</strong> least 4 hours before the start of the s<strong>es</strong>sion or the day before<br />
for early morning s<strong>es</strong>sions.<br />
S<strong>at</strong>urday October 6th 11:00 - 18:30<br />
Sunday October 7th 07:30 - 17:00<br />
Monday October 8th 07:30 - 18:20<br />
Tu<strong>es</strong>day October 9th 07:30 - 14:00<br />
CLOAKROOM - OPENING HOURS<br />
S<strong>at</strong>urday October 6th 11:30 - 21:00<br />
Sunday October 7th 07:30 - 17:30<br />
Monday October 8th 07:30 - 18:45<br />
Tu<strong>es</strong>day October 9th 08:30 - 15:30<br />
ELECTRONIC DEVICES<br />
As a court<strong>es</strong>y to your colleagu<strong>es</strong>, we invite you to turn off or silence all electronic<br />
devic<strong>es</strong> during the educ<strong>at</strong>ional, plenary s<strong>es</strong>sions and symposiums.<br />
BUSINESS CENTRE<br />
A Busin<strong>es</strong>s Centre with computer faciliti<strong>es</strong> is available on the first floor, in the<br />
exhibitor area.<br />
WIFI<br />
Internet acc<strong>es</strong>s is available through WIFI connection in the Busin<strong>es</strong>s Centre and<br />
in the exhibitor area.<br />
CATERING FACILITIES<br />
Lunch box<strong>es</strong> will be served in the exhibitor area, <strong>at</strong> the time specified in the<br />
programme. Coffee breaks will be also provided during the Congr<strong>es</strong>s.<br />
MEANS OF TRANSPORT<br />
Airport<br />
The Nice Côte d’Azur Airport is France’s second-larg<strong>es</strong>t intern<strong>at</strong>ional airport. It<br />
is loc<strong>at</strong>ed 15 minut<strong>es</strong> from the Acropolis (7 km from the city centre). More than<br />
50 airlin<strong>es</strong> provide regular service to d<strong>es</strong>tin<strong>at</strong>ions throughout the world. An<br />
80-minute flight links Nice to Paris, and is offered 23 tim<strong>es</strong> a day.<br />
http://en.nice.aeroport.fr<br />
Bus and tramway<br />
The transport network «Ligne d’azur» propos<strong>es</strong> a single r<strong>at</strong>e on the whole Urban<br />
Community of Nice Côte d’Azur which includ<strong>es</strong> 24 municipaliti<strong>es</strong>.<br />
The proposed r<strong>at</strong>e is fixed <strong>at</strong> 1euro both for the transport network by bus and<br />
by tram.<br />
Azur n°: +33 (0)810 061 006 (price local call)<br />
www.tramway-nice.org<br />
www.lignedazur.com<br />
« Vélos bleus » bik<strong>es</strong><br />
900 bik<strong>es</strong> are available in 90 st<strong>at</strong>ions distributed all over the city.<br />
R<strong>at</strong><strong>es</strong> are <strong>es</strong>tablished as follow:<br />
- The first half an hour: free acc<strong>es</strong>s (Subject to subscription)<br />
- Between ½ an hour and 1 hour: 1 €<br />
- Additional hour: 2 € per additional hour<br />
Azur n°: +33 (0)810 061 006 (price local call)<br />
Or: +33 (0)4 93 72 06 06<br />
www.velobleu.org<br />
Taxis<br />
The customers have to pay only the price shown on the meter of taxis.<br />
It is strongly recommended to the customers to require a receipt on behalf of<br />
the taxi drivers.<br />
Central r<strong>es</strong>erv<strong>at</strong>ions office n°: +33 (0)4 93 13 78 78
<strong>Programme</strong> <strong>at</strong> a <strong>Glance</strong><br />
S<strong>at</strong>urday October 6th<br />
AUDITORIUM 1<br />
ATHÉNA<br />
AUDITORIUM 2<br />
HERMÈS<br />
12:00 Registr<strong>at</strong>ion<br />
14:00-15:00 New oral anticoagulant<br />
tre<strong>at</strong>ments: the role of<br />
labor<strong>at</strong>ory<br />
15:30-16:30 Which antipl<strong>at</strong>elet agent<br />
for whom?<br />
Educ<strong>at</strong>ional S<strong>es</strong>sions<br />
Methology and<br />
st<strong>at</strong>istics : How to<br />
interprete a clinical<br />
assay<br />
Form<strong>at</strong>ion of<br />
the clot<br />
16:30-17:00 Break<br />
Opening ceremony<br />
17:00-17:30 Welcome<br />
17:30-18:15 Plenary Lecture: The<br />
origins of mediterranean<br />
popul<strong>at</strong>ion determined by<br />
molecular anthropology<br />
18:45-19:45 Concert<br />
Soloist Bouzouki:<br />
Nicolas Syros<br />
Title: Canto General<br />
Orch<strong>es</strong>tra and choirs:<br />
L<strong>es</strong> Chants de Thau<br />
Poems: Pablo Neruda;<br />
Music: Mikis Theodorakis<br />
Direction: Antoine Alleman<br />
AUDITORIUM 3<br />
RHODES<br />
Life thre<strong>at</strong>ening<br />
perioper<strong>at</strong>ive<br />
bleeding<br />
Circul<strong>at</strong>ing<br />
biomarkers<br />
19:50-21:00 Welcome Cocktail anim<strong>at</strong>ed by Nicolas Syros with his musicians<br />
Greek contemporary music<br />
Monday October 8th<br />
AUDITORIUM 1<br />
ATHÉNA<br />
AUDITORIUM 2<br />
HERMÈS<br />
08:30-09:45 Women's health<br />
Scientific Symposia<br />
Thrombosis in<br />
p<strong>at</strong>ients with<br />
hemorrhagic<br />
disorder<br />
10:00-11:00 Oral Communic<strong>at</strong>ions<br />
11:00-11:30<br />
Plenary S<strong>es</strong>sions<br />
Coffee Break<br />
11:30-12:10 Tissue factor and cancer<br />
12:10-12:40 New insights in <strong>at</strong>rial<br />
fibrill<strong>at</strong>ion<br />
13:45-14:30 Lunch Break<br />
14:30-15:30 Hot Topic S<strong>es</strong>sion 2<br />
15:30-17:00 Oral Communic<strong>at</strong>ions<br />
Plenary S<strong>es</strong>sions<br />
17:00-17:40 New insights into the<br />
contact activ<strong>at</strong>ion system<br />
17:40-18:20 Angiogen<strong>es</strong>is<br />
GALA DINNER<br />
AUDITORIUM 3<br />
RHODES<br />
Microparticul<strong>es</strong><br />
Sunday October 7th<br />
AUDITORIUM 1<br />
ATHÉNA<br />
AUDITORIUM 2<br />
HERMÈS<br />
Plenary S<strong>es</strong>sions<br />
08:30-09:10 Mechanisms of variability<br />
in antipl<strong>at</strong>elet agents<br />
r<strong>es</strong>ponse<br />
09:10-09:45 New antipl<strong>at</strong>elet agents:<br />
the end of r<strong>es</strong>istance ?<br />
10:00-11:00 Oral Communic<strong>at</strong>ions<br />
11:00-11:30 Coffee Break<br />
Scientific Symposia<br />
11:30-12:40 Thrombosis after surgical<br />
procedur<strong>es</strong><br />
Thrombosis and<br />
cancer: prevention<br />
and tre<strong>at</strong>ment<br />
S<strong>at</strong>ellite Symposia<br />
12:45-14:15 Changing landscape<br />
in anticoagul<strong>at</strong>ion<br />
– new perspectiv<strong>es</strong><br />
and tre<strong>at</strong>ment<br />
str<strong>at</strong>egi<strong>es</strong><br />
(12:45-13:45)<br />
14:15-14:45 Break<br />
Plenary S<strong>es</strong>sions<br />
14:50-15:30 New oral anticoagulant<br />
tre<strong>at</strong>ments in deep vein<br />
thrombosis<br />
15:30-16:15 New insights in <strong>at</strong>rial<br />
fibrill<strong>at</strong>ion<br />
16:20-17:50 Hot Topic S<strong>es</strong>sion 1<br />
Tu<strong>es</strong>day October 9th<br />
AUDITORIUM 1<br />
ATHÉNA<br />
08:30-09:45 Antiphospholipid<br />
antibodi<strong>es</strong><br />
AUDITORIUM 2<br />
HERMÈS<br />
Scientific Symposia<br />
Drug-induced<br />
thrombosis<br />
10:00-11:15 Oral Communic<strong>at</strong>ions<br />
11:15-11:45 Coffee Break<br />
Plenary S<strong>es</strong>sions<br />
11:45-12:20 Wh<strong>at</strong> did we learn from<br />
new oral anticoagulant<br />
tre<strong>at</strong>ment?<br />
12:20-13:00 Endothelial progenitor<br />
cells and therapeutic<br />
angiogen<strong>es</strong>is<br />
14:00-15:30 Oral Communic<strong>at</strong>ions<br />
POSTER SESSION<br />
17:50-18:30 Sunday October 7th<br />
12:45-13:45 Monday October 8th<br />
13:00-14:00 Tu<strong>es</strong>day October 9th<br />
AUDITORIUM 3<br />
RHODES<br />
Unusual<br />
thrombosis<br />
sit<strong>es</strong><br />
New<br />
Anticoagulants<br />
AUDITORIUM 3<br />
RHODES<br />
Antithrombotic<br />
agents and<br />
invasive<br />
procedur<strong>es</strong><br />
ROOM GALLIENI 5<br />
Sunday October 7th<br />
Councillors and<br />
13:00-14:30<br />
Found<strong>at</strong>ion Meeting<br />
Monday October 8th<br />
12:45-13:45 General Assembly
Scientific <strong>Programme</strong><br />
S<strong>at</strong>urday October 6th<br />
12:00 Registr<strong>at</strong>ion<br />
14:00 - 16:30 Educ<strong>at</strong>ional S<strong>es</strong>sions<br />
14:00 - 15:00 First s<strong>es</strong>sion<br />
New oral anticoagulant tre<strong>at</strong>ments: the role of<br />
labor<strong>at</strong>ory (Auditorium Athéna)<br />
Armando Tripodi<br />
Meyer Michel Samama<br />
Methology and st<strong>at</strong>istics: How to interprete a clinical<br />
assay (Auditorium Hermès)<br />
P<strong>at</strong>rick Mismetti<br />
Life thre<strong>at</strong>ening perioper<strong>at</strong>ive bleeding<br />
(Auditorium Rhod<strong>es</strong>)<br />
Charl<strong>es</strong> Marc Samama<br />
15:30 - 16:30 Second s<strong>es</strong>sion<br />
15:30-16:30 Which antipl<strong>at</strong>elet agent for whom? (Auditorium Athéna)<br />
Ariel Cohen<br />
Form<strong>at</strong>ion of the clot (Auditorium Hermès)<br />
Bruce Furie<br />
Circul<strong>at</strong>ing biomarkers (Auditorium Rhod<strong>es</strong>)<br />
Lina Badimon<br />
16:30-17:00 Break<br />
17:00-17:30 Opening ceremony (Auditorium Athéna)<br />
Welcome<br />
Jean Francois Schved, Pr<strong>es</strong>ident of the Congr<strong>es</strong>s<br />
Pier M. Mannucci, Pr<strong>es</strong>ident of the MLTD<br />
Meyer Michel Samama, Honorary Pr<strong>es</strong>ident of the Congr<strong>es</strong>s<br />
17:30-18:15 Plenary Lecture: The origins of mediterranean popul<strong>at</strong>ion<br />
determined by molecular anthropology<br />
Jacqu<strong>es</strong> Chiaroni<br />
18:45-19:45 Concert<br />
Soloist Bouzouki: Nicolas Syros<br />
Title: Canto General<br />
Orch<strong>es</strong>tra and choirs: L<strong>es</strong> Chants de Thau<br />
Poems: Pablo Neruda;<br />
Music: Mikis Theodorakis<br />
Direction: Antoine Alleman<br />
19:50-21:00 Welcome Cock<strong>at</strong>il<br />
anim<strong>at</strong>ed by Nicolas Syros with his musicians<br />
Greek contemporary music<br />
Sunday October 7th<br />
08:30-09:45 Plenary S<strong>es</strong>sion (Auditorium Athéna)<br />
Chair: María Ter<strong>es</strong>a Santos<br />
08:30-09:10 Mechanisms of variability in antipl<strong>at</strong>elet agents<br />
r<strong>es</strong>ponse<br />
Marco C<strong>at</strong>taneo<br />
09:10-09:45 New antiplagents agents: the end of r<strong>es</strong>istance?<br />
Stephanie Schultz<br />
10:00-11:00 Oral Communic<strong>at</strong>ions (CO1, CO2, CO3)<br />
CO1: New oral antithrombotics (Auditorium Athéna)<br />
Chairs: P<strong>at</strong>rik Mismetti and Ola E. Dahl<br />
C0126 VALUE-BASED PRICING FOR DABIGATRAN, RIVAR-<br />
OXABAN AND APIXABAN IN PATIENTS WITH NON-<br />
VALVULAR ATRIAL FIBRILLATION IN GERMANY<br />
Martin Krejczy, Svetlana Marx, Konrad Obermann, Martin<br />
Wehling, Job Harenberg<br />
C0131 COMPARISON OF THE EFFICACY AND SAFETY OF<br />
DABIGATRAN, RIVAROXABAN AND APIXABAN IN<br />
PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLA-<br />
TION USING NETWORK META-ANALYSIS<br />
Svetlana Marx, Job Harenberg, Martin Wehling, Christel<br />
Weiss, Hans-Christoph Diener, Victor J. Marder, Gregory<br />
Y.H. Lip<br />
C0227 INDIRECT COMPARISON OF THE EFFICACY AND<br />
SAFETY OF DABIGATRAN, RIVAROXABAN AND<br />
APIXABAN IN ELECTIVE TOTAL KNEE AND HIP RE-<br />
PLACEMENT SURGERY<br />
Svetlana Marx, Christel Weiss, Martin Wehling, Hanns-<br />
Peter Scharf, Ola Dahl, Job Harenberg<br />
C0295 MEASUREMENT OF DABIGATRAN AND RIVAR-<br />
OXABAN IN PRIMARY PREVENTION OF VENOUS<br />
THROMBOEMBOLISM IN 106 PATIENTS, WHO HAVE<br />
UNDERGONE MAJOR ORTHOPEDIC SURGERY. AN<br />
OBSERVATIONAL STUDY<br />
Samama Meyer Michel, Guinet Celine, Le Flem Lena,<br />
Ninin Emmanuel, Debue Jean-Marc<br />
CO2: Pl<strong>at</strong>elets (1) (Auditorium Hermès)<br />
Chairs: Anthi Travlou and Mojca Stegnar<br />
C0195 THE PRESENCE OF THE TXA2 RECEPTOR IN LIPID<br />
RAFTS OF PLATELETS IS NECESSARY FOR PLATELET<br />
ACTIVATION BY TXA2<br />
Antonio Moscardó, Juana Vallés, Isabel Madrid, Ana L<strong>at</strong>orre,<br />
Ángel<strong>es</strong> Dasí, María Ter<strong>es</strong>a Santos<br />
C0188 THE ACETYLATION OF TUBULIN REGULATES DENSE<br />
GRANULE RELEASE IN HUMAN PLATELETS<br />
Antonio Moscardó, María Ter<strong>es</strong>a Santos, Ana L<strong>at</strong>orre,<br />
Isabel Madrid, Juana Vallés<br />
C0343 POLYMORPHISMS OF PROTEIN TYROSINE PHOS-<br />
PHATASE CD148 INFLUENCE FCGAMMARIIA-DE-<br />
PENDENT PLATELET ACTIVATION AND THE RISK OF<br />
HEPARIN-INDUCED THROMBOCYTOPENIA<br />
Rollin Jerome, Pouplard Claire, Gr<strong>at</strong>acap Marie-Pierre,<br />
Leroux Dorothee, Aupart Michel, May Marc-Antoine, Gouilleux-Gruart<br />
Valerie, Payrastre Bernard, Gruel Yv<strong>es</strong><br />
CO3: Fibrinogen (Auditorium Rhod<strong>es</strong>)<br />
Chairs: Pierre Toulon and Ana Bronic<br />
C0113 IMPACT OF DIRECT THROMBIN AND DIRECT F XA<br />
INHIBITOR ANTICOAGULANTS ON ACL TOP FAMILY<br />
FIBRINOGEN ASSAYS<br />
Janet Callahan, Karen DiStasio, Denise M<strong>at</strong>te, Mary Doyle,<br />
Mark Triscott, Philippe Lacombe
C0260 MUTATION IN FIBRINOGEN POLYMERIZATION<br />
POCKET ASSOCIATED WITH THROMBOSIS<br />
Roman Kotlin, Jiri Suttnar, Kristyna Pimkova, Vera Geierova,<br />
Jan Evangelista Dyr<br />
C0096 ASSESSING THE COMBINED EFFECTS TWO SIN-<br />
GLE NUCLEOTIDE GENETIC POLYMORPHISMS OF<br />
FIBRINOGEN GENES ON THE COAGULATION CAS-<br />
CADE IN PATIENTS WITH STABLE ANGINA<br />
Zoi Pallantza, Stavros Kontos, Maria Kozanitou, Stilianos<br />
Gr<strong>at</strong>sias, Athanasia Lazaraki, Maria Eleni Mplouna, Nikolaos<br />
Papageorgiou, Dimitrios Tousoulis, Antigoni Miliou,<br />
Christodoulos Stefanadis, Zoi Pallantza<br />
C0127 EVALUATION OF NEW AUTOMATIZED SOLUBLE FI-<br />
BRIN/FIBRIN MONOMER METHOD<br />
Eli W<strong>es</strong>terlund, Jaak Eintrei, Lisbeth Söderblom, Jovan P<br />
Antovic<br />
11:00-11:30 Coffee Break<br />
11:30-12:40 Scientific Symposia<br />
Thrombosis after surgical procedur<strong>es</strong> (Auditorium Athéna)<br />
Chairs: Charl<strong>es</strong> Marc Samama and Virginie Siguret<br />
Asymptom<strong>at</strong>ic distal DVT is not a surrog<strong>at</strong>e end-point<br />
Charl<strong>es</strong> Marc Samama<br />
Bleeding definitions in orthopaedic VTE prophylaxis<br />
trials: a real need for standardiz<strong>at</strong>ion<br />
Ola E. Dahl<br />
Should we follow the 9th ACCP guidelin<strong>es</strong>?<br />
Juan Ignacio Arcelus Martínez<br />
Thrombosis and cancer: prevention and tre<strong>at</strong>ment<br />
(Auditorium Hermès)<br />
Chairs: Ismail Elalamy and Abdulkareem Almomen<br />
Aspirin and colorectal cancer<br />
Christophe Dubois<br />
Multiple myeloma: epidemiology and risk factors<br />
Xavier Leleu<br />
Thrombosis during myeloma: prevention and tre<strong>at</strong>ment<br />
Grégoire Le Gal<br />
Unusual thrombosis sit<strong>es</strong> (Auditorium Rhod<strong>es</strong>)<br />
Chairs: Uri Seligsohn and Tazi Mezalek Zoubida<br />
Cerebral venous thrombosis, pregnancy and<br />
contraception<br />
Marie-Germaine Bousser<br />
Splanchnic thrombosis<br />
Walter Ageno<br />
Mondor disease<br />
Jean-Pierre Laroche<br />
12:45-13:45 S<strong>at</strong>ellite Symposia (Auditorium Hermès)<br />
12:45-13:45 Changing landscape in<br />
anticoagul<strong>at</strong>ion – new perspectiv<strong>es</strong><br />
and tre<strong>at</strong>ment str<strong>at</strong>egi<strong>es</strong><br />
12:45 WELCOME & INTRODUCTION<br />
Chair: P<strong>at</strong>rick Mismetti<br />
12:50 NOVEL ANTICOAGULANTS – NEW PERSPECTIVES<br />
IN ATRIAL FIBRILLATION<br />
José Luis Zamorano<br />
13:05 CURRENT LANDSCAPE OF VENOUS THROMBOEM-<br />
BOLISM – THE CLINICIAN’S VIEW<br />
P<strong>at</strong>rick Mismetti<br />
13:25 NEW DIRECTIONS IN VENOUS THROMBOEMBO-<br />
LISM MANAGEMENT<br />
Walter Ageno<br />
13:35 PANEL DISCUSSION & MEETING CLOSE<br />
All<br />
12:45-14:15 S<strong>at</strong>ellite Symposia (Auditorium Rhod<strong>es</strong>)<br />
New Anticoagulants<br />
Chair: Yv<strong>es</strong> Gruel<br />
12:45 Welcome and Introduction<br />
Yv<strong>es</strong> Gruel<br />
12:50 Pharmacology of new anticoagulants: the key<br />
aspects<br />
Armando D’Angelo<br />
13:15 Effects of noacs on hemostasis: practical<br />
consequenc<strong>es</strong> for the biologist<br />
Carlos Aguilar<br />
13:45 Management of p<strong>at</strong>ients tre<strong>at</strong>ed with noacs in<br />
emergent clinical situ<strong>at</strong>ions<br />
Yv<strong>es</strong> Gruel<br />
14:10 Concluding Remarks<br />
Yv<strong>es</strong> Gruel<br />
13:00-14:30 Councillors and Found<strong>at</strong>ion Meeting (Room Gallieni 5)<br />
14:15-14:45 BREAK<br />
14:50-16:15 Plenary S<strong>es</strong>sion (Auditorium Athéna)<br />
Chair: Meyer Michel Samama<br />
14:50-15:30 New oral anticoagulant tre<strong>at</strong>ments in deep vein<br />
thrombosis<br />
Pierre Fontana<br />
15:30- 16:15 Thrombosis in hem<strong>at</strong>ologic malignanci<strong>es</strong><br />
Anna Falanga<br />
16:20-17:50 HOT TOPICS SESSION 1 (Auditorium Hermès)<br />
Chairs: Silvy Laporte and Sergio Coccheri<br />
C0313 CLINICALLY RELEVANT NON-MAJOR BLEEDING: A<br />
SURROGATE ENDPOINT FOR MAJOR BLEEDING?<br />
VALIDATION BY META-ANALYSIS OF RANDOMIZED<br />
CLINICAL TRIALS IN MAJOR ORTHOPEDIC SUR-<br />
GERY, VENOUS THROMBOEMBOLIC TREATMENT<br />
AND ATRIAL FIBRILLATION<br />
Laporte Silvy, Mismetti P<strong>at</strong>rick, Chapelle Céline, Bertoletti<br />
Laurent, Merah Adel, Lega Jean-Christophe, Décousus<br />
Hervé<br />
C0346 ARE PATIENTS EXPOSED TO ANTIPSYCHOTICS TRU-<br />
LY AT RISK OF VENOUS THROMBOEMBOLISM?<br />
Céline Chapelle, Sara Quenet, Xavier Delavenne, Karine<br />
Lacut, P<strong>at</strong>rick Mismetti, Silvy Laporte, Marie-Noëlle Beyens<br />
C0416 HIGH LIPOPROTEIN(A) AND HOMOCYSTEINE LEVELS<br />
ARE ASSOCIATED TO THE EXTENSION OF ATHERO-<br />
SCLEROTIC DISEASE IN ACUTE CORONARY SYN-<br />
DROME PATIENTS.<br />
Gabriele Cioni, Rossella Marcucci, Serafina Valente, Cristina<br />
Giglioli, Rosanna Abb<strong>at</strong>e, Maria Boddi<br />
C0419 IS PROTHROMBIN TIME A PREDICTOR OF NEW-ON-<br />
SET DIABETES IN HYPERTENSIVE AND CORONARY<br />
HEART DISEASE PATIENTS?<br />
Gwo-Ping Jong, Tsochiang Ma<br />
C0213 FIGHTING FOR ACUTE PULMONARY EMBOLISM IN<br />
RUSSIA<br />
Igor Bokarev, Aleksandr Medvedev<br />
C0016 INTERNATIONAL GOOD CLINICAL PRACTICES (GCP)<br />
GUIDELINES FOR ANTITHROMBOTICS IN CANCER<br />
PATIENTS<br />
D Farge-Bancel, P Debourdeau<br />
17:50-18:30 Posters S<strong>es</strong>sion (PS1) (Foyer)
08:30-09:45 Scientific Symposia<br />
Monday October 8th<br />
08:30-09:45 Women's health (Auditorium Athéna)<br />
Chairs: Jacqueline Conard and Per Morten Sandset<br />
Estrogens and cardiovascular risk in menopausal<br />
women: benefit or harm?<br />
Jean-François Arnal<br />
Estrogens, prog<strong>es</strong>tins, <strong>es</strong>trogenicity and new<br />
contraceptions<br />
Regine Sitruk-Ware<br />
Contraception, venous thrombosis and biological<br />
plausability<br />
Geneviève Plu-Bureau<br />
Thrombosis in p<strong>at</strong>ients with hemorrhagic disorder<br />
(Auditorium Hermès)<br />
Chairs: Emma Gouider and Paolo Prandoni<br />
Thrombosis during PTI<br />
Mette Nørgaard<br />
Thrombosis in factor VII deficiency<br />
Muriel Giansily Blaizot<br />
Thrombosis in haemophiliacs<br />
Cedric Hermans<br />
Surgery in hemophiliacs: is thromboprophylaxis<br />
mand<strong>at</strong>ed?<br />
Margareth Castro-Ozelo<br />
Microparticul<strong>es</strong> (Auditorium Rhod<strong>es</strong>)<br />
Chairs: Françoise Dign<strong>at</strong>-George and An<strong>at</strong> Aharon<br />
Microparticl<strong>es</strong> in vascular disorders<br />
Rienk Niewland<br />
Microparticl<strong>es</strong>, endothelial dysfunction and<br />
<strong>at</strong>herothrombosis<br />
Chantal Boulanger<br />
Microparticl<strong>es</strong>, angiogen<strong>es</strong>is and cancer<br />
David Varon<br />
10:00-11:00 Oral Communic<strong>at</strong>ions (CO4, CO5, CO6)<br />
CO4 : New oral anticoagulants (Auditorium Athéna)<br />
Chairs: Gin<strong>es</strong> Escolar and Job Harenberg<br />
C0122 EFFECTS OF APIXABAN ON HEMOSTASIS AND RE-<br />
VERSAL OF ITS ANTICOAGULANT ACTION BY DIF-<br />
FERENT COAGULATION FACTOR CONCENTRATES:<br />
STUDIES IN VITRO WITH CIRCULATING HUMAN<br />
BLOOD<br />
Gin<strong>es</strong> Escolar, Eduardo Arellano-Rodrigo, Juan Carlos<br />
Reverter, Jaume Villalta, Victoria Veronica Sanz, P<strong>at</strong>ricia<br />
Molina, Maribel Diaz-Ricart, Ana Maria Galan<br />
C0139 REVERSAL OF RIVAROXABAN-INDUCED PROLON-<br />
GATION OF CLOTTING TIME WITH PROTHROMBIN<br />
COMPLEX CONCENTRATE (PCC), ACTIVATED PRO-<br />
THROMBIN COMPLEX CONCENTRATE (APCC) AND<br />
RECOMBINANT FACTOR VIIA (RFVIIA) IN VITRO<br />
Elizabeth Perzborn, Stefan Heitmeier, Volker Laux<br />
C0190 INFLUENCE OF AGE AND RENAL FUNCTION ON THE<br />
CONCENTRATION OF RIVAROXABAN IN PLASMA<br />
AND URINE IN PATIENTS UNDERGOING PRIMARY<br />
ELECTIVE TOTAL KNEE AND HIP REPLACEMENT<br />
SURGERY<br />
Astrid Schulze, Svetlana Marx, Christel Weiss, Job<br />
Harenberg<br />
C0353 UNITED KINGDOM CONSENSUS BASED PRACTICAL<br />
GUIDE FOR THE MANAGEMENT OF HAEMORRHAGE<br />
IN PATIENTS RECEIVING DABIGATRAN<br />
Raza Alikhan, Rachel Rayment, Trevor Baglin, Gary Benson,<br />
Laura Green, David Keeling, Scott Marshall, Raj P<strong>at</strong>el,<br />
Sue Pavord, Peter Rose, Campbell Tait<br />
CO5: Pl<strong>at</strong>elets (2) (Auditorium Hermès)<br />
Chair: Thomas Lecompte<br />
C0166 THE RELATIONSHIP BETWEEN PLATELET GLYCO-<br />
PROTEIN IIB RS5911 POLYMORPHISM AND IN-<br />
FLAMMATION IN COPD PATIENTS<br />
Hilal Altinoz, Samet Ergun, Koray Ak, Zehra Oya Uyguner,<br />
Turay Yardimci, Sermin Tetik<br />
C0363 DISCOID PLATELET AGGREGATIONS VISUALIZED BY<br />
IN VIVO MOLECULAR IMAGING, AND CONTRIBU-<br />
TION OF INFLAMMATORY CYTOKINES<br />
S<strong>at</strong>oshi Nishimura, Mika Nagasaki, Ryozo Nagai<br />
C0347 THROMBIN BINDING TO PLATELETS OF YOUNG PA-<br />
TIENTS WITH A HISTORY OF ACUTE MYOCARDIAL<br />
INFARCTION<br />
Grazia Loredana Mendolicchio, Monica Bacci, Dennis<br />
Zavalloni, Lidia Rota, Zaverio Marcello Ruggeri<br />
C0063 DOWN REGULATION OF PLATELET ACTIVATION<br />
MARKERS DURING LONG-TERM IMMOBILIZATION<br />
Karin Arinell, Ole Fröbert, Stéphane Blanc, Anders Larsson,<br />
Kjeld Christensen<br />
CO6: Perin<strong>at</strong>al and pedi<strong>at</strong>ric hemostasis (Auditorium<br />
Rhod<strong>es</strong>)<br />
Chairs: Nej<strong>at</strong> Akar and Pierre-Emmanuel Morange<br />
C0160 NEONATAL THROMBOSIS: INFLUENCE OF ETHNICI-<br />
TY ON GENETIC RISK FACTORS<br />
Carina Levin, M. Peniakov, C. Felszer, D. Reich, S Shalev,<br />
Ariel Koren<br />
C0240 SAFETY AND EFFICACY OF ANTICOAGULATION IN<br />
CEREBRAL SINUS THROMBOSIS IN CHILDREN: A<br />
SINGLE CENTER EXPERIENCE<br />
Angel<strong>es</strong> Dasi, Sara Izquierdo, Bienvenida Argil<strong>es</strong><br />
C0369 FACTOR V LEIDEN AND PROTHROMBIN 20210A<br />
MUTATIONS AMONG TURKISH PEDIATRIC LEUKE-<br />
MIA PATIENTS<br />
Dilara F<strong>at</strong>ma Akin, Kadir Sipahi, Tuğba Kayaalp, Yonca<br />
Eğin, Serpil Taşdelen, Emin Kürekçi, Üstün Ezer, Nej<strong>at</strong> Akar<br />
C0382 THE ROLE OF THROMBOPHILIA IN THE PERINATAL<br />
STROKE IN NEONATES: A RETROSPECTIVE STUDY<br />
IN 54 CASES<br />
M. Luciani, M. Bal<strong>es</strong>tri, K. Girardi, L. Altomare, M. Sold<strong>at</strong>i,<br />
S. Pancotti, A. Minozzi, G. Avvis<strong>at</strong>i, F. Loc<strong>at</strong>elli<br />
11:00-11:30 Coffee Break<br />
11:30-12:40 Plenary S<strong>es</strong>sion (Auditorium Athéna)<br />
Chair: Maria Benedetta Don<strong>at</strong>i<br />
11:30-12:10 Tissue factor and cancer<br />
Wolfram Ruf<br />
12:10-12:40 New insights in <strong>at</strong>rial fibrill<strong>at</strong>ion<br />
Jean-Yv<strong>es</strong> Le Heuzey<br />
12:45-13:45 General Assembly (Room Galliani 5)<br />
12:45-13:45 Posters s<strong>es</strong>sion (PS2) (Foyer)<br />
13:45-14:30 Lunch Break<br />
14:30-15:30 Hot Topic S<strong>es</strong>sion 2 (Auditorium Hermès)<br />
Chair: Hervé Decousus and Franc<strong>es</strong>co Dentali<br />
C0427 SYSTEMATIC REVIEW AND PATIENT-LEVEL META-<br />
ANALYSIS: RESIDUAL VENOUS OBSTRUCTION TO<br />
PREDICT RECURRENCE OF VENOUS THROMBOEM-<br />
BOLISM AFTER UNPROVOKED DEEP VEIN THROM-<br />
BOSIS<br />
Marco Paolo Donadini, Walter Ageno, Benilde Cosmi,<br />
Gregory Le Gal, Daniela Poli, Paolo Prandoni, Marco Rodger,<br />
Sergio Siracusa, Laura Young, M<strong>at</strong>teo Bonzini, Monica<br />
Caprioli, Franc<strong>es</strong>co Dentali, Alfonso Dorio, Jam<strong>es</strong> Douketis
C0413 LACK OF ASSOCIATION BETWEEN BLOOD VISCOS-<br />
ITY AND THROMBOTIC EVENTS IN PATIENTS WITH<br />
SYSTEMIC LUPUS ERYTHEMATOSUS.<br />
A. Vayá, E. Bonet, C. Alcalá, JM. Ricart<br />
C0060 CHRONIC OBSTRUCTIVE PULMONARY DISEASE IS<br />
NOT ASSOCIATED WITH FUTURE RISK OF VENOUS<br />
THROMBOEMBOLISM IN A GENERAL POPULATION<br />
- THE TROMSØ STUDY<br />
Trond Børvik, Sigrid K. Brækkan, Hasse Melbye, John-<br />
Bjarne Hansen<br />
C0250 THE APS PIEDMONT COHORT: APL PROFILE AND<br />
RISK FACTORS FOR THROMBOTIC RECURRENCES<br />
Mario Bazzan, Antonella Vaccarino, Stefania Stella, Ren<strong>at</strong>o<br />
Carignola, Maria Tiziana Bertero, Barbara Montaruli,<br />
Dario Rocc<strong>at</strong>ello<br />
15:30-17:00 Oral Communic<strong>at</strong>ions (CO7, CO8, CO9)<br />
CO7: Antivitamin K (Auditorium Athéna)<br />
Chairs: Armando Tripodi and Isabelle Gouin-Thibault<br />
C0310 RISK STRATIFICATION MODELS TO PREDICT BLEED-<br />
ING EVENTS IN VERY OLD PATIENTS ON VKA<br />
TREATMENT FOR VENOUS THROMBOEMBOLISM.<br />
RESULTS OF A PROSPECTIVE MULTICENTER STUDY<br />
Daniela Poli, Emilia Antonucci, Sophie T<strong>es</strong>ta, Benilde Cosmi,<br />
Gualtiero Palareti, Walter Ageno<br />
C0047 PHARMACOGENETIC TESTS COULD BE HELPFUL IN<br />
PREDICTING OF VKA MAINTENANCE DOSE IN EL-<br />
DERLY PATIENTS AT TREATMENT INITIATION<br />
Mirjana Kovac, Ljiljana Rakicevic, Jelena Kusic-Tisma,<br />
Dragica Radojkovic<br />
C0323 PREDICTION MODEL OF FLUINDIONE MAINTE-<br />
NANCE DOSE (A NON-COUMARIN VITAMIN K<br />
ANTAGONIST) IN THE ELDERLY INCLUDES BODY-<br />
WEIGHT, AMIODARONE INTAKE, VKORC1, CYP4F2,<br />
ABCB1 GENOTYPES BUT NOT CYP2C9 GENOTYPE<br />
Moreau Caroline, Berndt Célia, Pautas Eric, Andro Marion,<br />
Mahe Isabelle, Lacut Karine, Le Gal Grégoire, Duverlie<br />
Charlotte, Lecorche Emmanuel, Gouin-Thibault Isabelle,<br />
Golmard Jean-Louis, Loriot Marie-Anne, Siguret Virginie<br />
C0356 EVALUATION OF INRPLUS, A PORTABLE DEVICE IN<br />
THE MANAGEMENT OF FLUINDIONE, AN ORAL AN-<br />
TICOAGULANT TREATMENT: A PROSPECTIVE CLUS-<br />
TER RANDOMIZED CONTROLLED, OPEN TRIAL.<br />
Pernod Gill<strong>es</strong>, Imbert P<strong>at</strong>rick, Jacquet Jean-Philippe,<br />
Bailly Cécile, Laporte Silvy, Lièvre Michel<br />
C0078 DOSE MODIFYING EFFECT OF VKORC1 9041G>A<br />
AND 6009C>T GENE- POLIMORPHISMS IN ACENO-<br />
COUMAROL ANTICOAGULATED HUNGARIAN OUT-<br />
PATIENTS<br />
Réka Móz<strong>es</strong>, Orsolya Tóth, Hajna Losonczy, Marianna<br />
Dávid, Barbara Réger, Béla Melegh, Ágn<strong>es</strong> Nagy<br />
C0149 LONG-TERM TREATMENT OF VENOUS THROMBO-<br />
EMBOLISM, WITH MODERATE-INTENSITY VITA-<br />
MIN-K ANTAGONISTS (VKA) (INR RANGE BETWEEN<br />
1.8 - 2.5), IMPROVE PATIENT COMFORT AND DE-<br />
CREASES TREATMENT COSTS, WITHOUT INCREAS-<br />
ING ADVERSE EFFECTS: A MATCHED PAIRED STUDY<br />
Franc<strong>es</strong>c J. Casals Solé<br />
CO8: Cardiac diseas<strong>es</strong> (Auditorium Hermès)<br />
Chair: Grigoris Gerotziafas<br />
C0316 EFFECTS OF HEMODYNAMIC FORCES ON TISSUE<br />
FACTOR RNA EXPRESSION IN HUMAN ENDOTHE-<br />
LIAL CELLS<br />
Bauer Sumpio<br />
C0386 A META-SYNTHESIS OF QUALITATIVE STUDIES<br />
EXPLORING PATIENTS’ AND HEALTHCARE PRO-<br />
FESSIONALS VIEWS OF ATRIAL FIBRILLATION AND<br />
ORAL ANTICOAGULANT THERAPY<br />
Christian Borg Xuereb, Rachel L. Shaw, Gregory Y.H. Lip,<br />
Deirdre A. Lane<br />
C0265 ELEVATED HOMOCYSTEINE LEVELS ARE ASSOCI-<br />
ATED WITH SYSTEMIC ATHEROSCLEROSIS IN PA-<br />
TIENTS WITH ACUTE CORONARY SYNDROME.<br />
Gabriele Cioni, Rossella Marcucci, Elisabetta Cappellini,<br />
Rosanna Abb<strong>at</strong>e, Maria Boddi<br />
C0129 EFFICACY AND SAFETY OF THE NOVEL ORAL ANTI-<br />
COAGULANTS IN ATRIAL FIBRILLATION: A SYSTEM-<br />
ATIC REVIEW AND META-ANALYSIS OF THE LITERA-<br />
TURE<br />
Franc<strong>es</strong>co Dentali, Nicoletta Riva, Mark Crowther, Alexander<br />
Turpie, Gregory Lip<br />
C0090 CAROTID ATHEROSCLEROSIS AND FUTURE RISK OF<br />
VENOUS THROMBOEMBOLISM AND MYOCARDIAL<br />
INFARCTION - THE TROMSØ STUDY<br />
Erin M<strong>at</strong>hi<strong>es</strong>en Hald, Caroline Lind, Ellisiv Bøgeberg<br />
M<strong>at</strong>hi<strong>es</strong>en, Tom Wilsgaard, Inger Njølstad, Sigrid Brækkan,<br />
John-Bjarne Hansen<br />
CO9: Microparticl<strong>es</strong> (Auditorium Rhod<strong>es</strong>)<br />
Chair: David Varon and Anne Marie Fischer<br />
C0074 INCREASED NUMBER OF CIRCULATING AND PLATE-<br />
LET-DERIVED MICROPARTICLES IN HUMAN BLOOD<br />
ENHANCES THROMBOSIS ON ATHEROSCLEROTIC<br />
PLAQUES<br />
Rosa Suad<strong>es</strong>, Ter<strong>es</strong>a Padró, Gemma Vilahur, Lina Badimon<br />
C0128 DECREASE OF MICROPARTICLES AND HEMOSTASIS<br />
IMPROVEMENT AFTER THE TREATMENT IN HEMO-<br />
PHILIA A. COINCIDENCE OR CAUSATION?<br />
Jovan P Antovic, Fariborz Mobbarez, Danijela Mikovic,<br />
Aleksandra Antovic<br />
C0082 CIRCULATING LEUKOCYTE- AND ENDOTHELIAL-DE-<br />
RIVED MICROPARTICLES SUPPORT A FIBRINOLYTIC<br />
ACTIVITY.<br />
Romaric Lacroix, Laurent Plawinski, Stéphane Robert,<br />
Loïc Doeuvre, Florence Sab<strong>at</strong>ier, Sara Martinez de Lizarrondo,<br />
Anna Mezzap<strong>es</strong>a, Francine Anfosso, Aurelie S. Leroyer,<br />
Pascale Poullin, Noémie Jourde, Sébastien M. Njock, Denis<br />
Vivien, Chantal M. Boulanger, Eduardo Angl<strong>es</strong>-Cano, Françoise<br />
Dign<strong>at</strong>-George<br />
C0431 MICROPARTICLE TF/ TFPI HEMOSTATIC BALANCE IN<br />
PHYSIOLOGICAL AND PATHOLOGICAL STATES<br />
An<strong>at</strong> Aharon, Benjamin Brenner<br />
C0059 CIRCULATING LEVELS OF P-SELECTIN GLYCOPRO-<br />
TEIN LIGAND-1 (PSGL-1) POSITIVE MICROPARTI-<br />
CLES ARE INCREASED IN PATIENTS WITH UNPRO-<br />
VOKED VENOUS THROMBOEMBOLISM<br />
Manjun<strong>at</strong>h Goolyam Basavaraj, John-Bjarne Hansen<br />
17:00-18:20 Plenary S<strong>es</strong>sion (Auditorium Athéna)<br />
Chair: Pier M. Mannucci<br />
17:00-17:40 New insights into the contact activ<strong>at</strong>ion system<br />
Thomas Renné<br />
17:40-18:20 Angiogen<strong>es</strong>is<br />
Augustin Hellmut<br />
GALA DINNER
Tu<strong>es</strong>day October 9th<br />
08:30-09:45 Scientific Symposia<br />
Antiphospholipid antibodi<strong>es</strong> (Auditorium Athéna)<br />
Chairs: Sami Guermazi and Denis Gerard Wahl<br />
ISTH Guidelin<strong>es</strong><br />
Vittorio Pengo<br />
Anti beta2 glycoprotein antibodi<strong>es</strong>: are they p<strong>at</strong>hogen?<br />
Bas de La<strong>at</strong><br />
Antiphospholipid antibodi<strong>es</strong>: evalu<strong>at</strong>ion of the<br />
thrombotic risk<br />
K<strong>at</strong>rien Devre<strong>es</strong>e<br />
Drug-induced thrombosis (Auditorium Hermès)<br />
Chairs: Sabine Eichinger and Jacqueline Conard<br />
Oral contraception in women with mild thrombophilia:<br />
wh<strong>at</strong> we’ve learned recently?<br />
Ángel<strong>es</strong> Blanco Molina<br />
Adjuvant therapy for Breast cancer and thrombosis<br />
Mario Mandala<br />
Thrombotic risk and antipsychotics<br />
Francis Couturaud<br />
Antithrombotic agents and invasive procedur<strong>es</strong><br />
(Auditorium Rhod<strong>es</strong>)<br />
Chair: Charl<strong>es</strong> Marc Samama<br />
Cardiologist point of view<br />
Jean-Philippe Collet<br />
An<strong>es</strong>th<strong>es</strong>iologist point of view<br />
Pierre Albaladejo<br />
Hem<strong>at</strong>ologist point of view<br />
Thomas Lecompte<br />
10:00-11:15 Oral Communic<strong>at</strong>ions (CO10, CO11, CO12)<br />
CO10: Deep vein thrombosis (Auditorium Athéna)<br />
Chair: Nevine Kassim<br />
C0170 PROPHYLAXIS OF THROMBOTIC COMPLICATIONS<br />
IN A PREGNANT PATIENTS WITH PROSTHETIC<br />
HEART VALVES<br />
Alexander Mak<strong>at</strong>sariya, Viktoriya Bitsadze, Dzhamilya<br />
Khizroeva, Svetlana Akinshina, N<strong>at</strong>alya Mak<strong>at</strong>sariya<br />
C0208 PREVENTION OF VENOUS THROMBOEMBOLISM IN<br />
ACUTELY ILL MEDICAL PATIENTS WITH RENAL IM-<br />
PAIRMENT: THE FONDAIR STUDY<br />
Walter Ageno, Nicoletta Riva, P<strong>at</strong>rizia Noris, Marcello Di<br />
Nisio, Micaela La Regina, Dimitriy Arioli, Luigi Ria, Valter<br />
Monzani, Stefano Cuppini, Enrico Lupia, M<strong>at</strong>teo Giorgi<br />
Pierfranc<strong>es</strong>chi, Franc<strong>es</strong>co Dentali<br />
C0302 PROGNOSTIC CLINICAL PREDICTION RULES TO<br />
IDENTIFY LOW-RISK PULMONARY EMBOLISM: A<br />
SYSTEMATIC REVIEW AND META-ANALYSIS<br />
Al<strong>es</strong>sandro Squizz<strong>at</strong>o, Marco P Donadini, Luca Galli,<br />
Franc<strong>es</strong>co Dentali, Drahomir Auj<strong>es</strong>ky, Walter Ageno<br />
C0322 FACTORS ASSOCIATED WITH THERAPEUTIC STRAT-<br />
EGIES IN PATIENTS WITH SPLANCHNIC VEIN<br />
THROMBOSIS: RESULTS OF AN INTERNATIONAL<br />
REGISTRY<br />
Nicoletta Riva, Walter Ageno, Sam Schulman, Soo-Mee<br />
Bang, Maria Ter<strong>es</strong>a Sartori, Elvira Grandone, Jan Beyer,<br />
Giovanni Barillari, Dario Di Minno, Rita Duce, Al<strong>es</strong>sandra<br />
Mal<strong>at</strong>o, Rita Santoro, Daniela Poli, Peter Verhamme, Ida<br />
Martinelli, Pieter Kamphuisen, Adriano Al<strong>at</strong>ri, Doyeun Oh,<br />
Elbio D’Amico, Franc<strong>es</strong>co Dentali<br />
C0383 DIAGNOSTIC ACCURACY OF LUNG ULTRASOUND<br />
FOR PULMONARY EMBOLISM: A META-ANALYSIS<br />
Al<strong>es</strong>sandro Squizz<strong>at</strong>o, Elena Rancan, Franc<strong>es</strong>co Dentali,<br />
Walter Ageno<br />
CO11: Vascular biology (Auditorium Hermès)<br />
Chairs: Amparo Estellés and Essam Aboelnazar<br />
Chairmen: Amparo Estell<strong>es</strong> and Klaus T. Preissner<br />
C0077 TISSUE FACTOR AND METALLOPROTEINASES EX-<br />
PRESSION IN TWO CELL THERAPY PRODUCTS:<br />
RELEVANCE FOR THE THROMBOGENICITY IN VAS-<br />
CULAR CELL THERAPY.<br />
Tournois Claire, Cuccuini Wendy, Poitevin Gael, Pignon<br />
Bernard, Sev<strong>es</strong>tre Marie Antoinette, Nguyen Philippe<br />
C0081 TISSUE FACTOR EXPRESSION AND MICRORNAS<br />
–17-5P AND –20A IN ENDOMETRIAL CELL CUL-<br />
TURES FROM WOMEN WITH ENDOMETRIOSIS: ITS<br />
MODULATION BY PERITONEAL FLUID<br />
Aitana Braza-Boils, Juan Gilabert-Estellés, Luis Andrés<br />
Ramón, Juan Gilabert Aguilar, Melitina Chirivella Casanova,<br />
Francisco España Furió, Amparo Estellés Cortés<br />
C0080 INFLUENCE OF PERITONEAL FLUID ON MICROR-<br />
NAS RELATED TO ANGIOGENESIS AND ANGIO-<br />
GENIC AND FIBRINOLYTIC FACTORS EXPRESSION<br />
IN STROMAL CELL CULTURES OF EUTOPIC ENDO-<br />
METRIA AND OVARIAN ENDOMETRIOMAS FROM<br />
WOMEN WITH ENDOMETRIOSIS<br />
Aitana Braza-Boils, Juan Gilabert-Estellés, Luis Andrés<br />
Ramón, Juan Gilabert Aguilar, Melitina Chirivella Casanova,<br />
Francisco España Furió, Amparo Estellés Cortés<br />
C0412 SOLUBLE CD146: A NEW ANGIOGENIC FACTOR IN-<br />
VOLVED IN PHYSIOPATHOLOGY<br />
Karim Harhouri, N<strong>at</strong>halie Bardin, Françoise Dign<strong>at</strong>-George,<br />
Marcel Blot-Chabaud<br />
CO125 IN VITRO EFFECT OF THE DIRECT XA INHIBITOR,<br />
APIXABAN, ON GLOBAL COAGULATION LABORATO-<br />
RY TESTS AND COAGULATION FACTOR ASSAYS:<br />
COMPARISON OF 10 APTT AND 10 PT REAGENTS,<br />
AND TWO COAGULOMETERS. A “GROUPE D’ETUDE<br />
SUR L’HÉMOSTASE ET LA THROMBOSE” STUDY.<br />
Gouin-Thibault Isabelle, Flaujac Claire, Horellou Marie-<br />
Hélène, Lacarrière Nicole, Lecompte Thomas<br />
CO12: Protein C (Auditorium Rhod<strong>es</strong>)<br />
Chairs: Charl<strong>es</strong> T. Esmon and Ismaïl Elalamy<br />
C0034 A SIMPLIFIED ASSAY FOR QUANTIFICATION OF CIR-<br />
CULATING ACTIVATED PROTEIN C LEVELS<br />
Elena Bonet, Laura Martos, Silvia Navarro, Pilar Medina,<br />
Amparo Estell<strong>es</strong>, Francisco España<br />
C0068 HAPLOTYPES OF THE ENDOTHELIAL PROTEIN C RE-<br />
CEPTOR GENE AND CIRCULATING PROTEIN C LEV-<br />
ELS<br />
Laura Martos, Elena Bonet, Pilar Medina, Silvia Navarro,<br />
Esther Zorio, Joaquín Rueda, José A. Aznar, Miguel A.<br />
Arnau, Ana M. Osa, Amparo Estellés, Rogier M. Bertina,<br />
Francisco España<br />
C0069 ASSOCIATION OF HAPLOTYPES (H) 1 AND 3 OF THE<br />
ENDOTHELIAL PROTEIN C RECEPTOR GENE (PROCR)<br />
WITH VENOUS THROMBOEMBOLISM<br />
Elena Bonet, Silvia Navarro, Pilar Medina, Laura Martos,<br />
Fernando Ferrando, Amparo Vayá, Yolanda Mira, José A.<br />
Aznar, Amparo Estellés, Rogier M. Bertina, Francisco España<br />
C0235 IDENTIFICATION OF MUTATIONS IN THE PROTEIN C<br />
GENE IN A PANEL OF 65 SPANISH FAMILIES WITH<br />
PROTEIN C DEFICIENCY<br />
Laura Martos, Silvia Navarro, Pilar Medina, Elena Bonet,<br />
María F. López-Fernández, Van<strong>es</strong>sa Roldán, Dolors Tássi<strong>es</strong>,<br />
Pascual Marco, Ignacio Alberca, Javier Corral, Yolanda<br />
Mira, Ramón Lecumberri, Gemma Iruin, Francisco Velasco,<br />
Juan C. Reverter, Fernando Ferrando, María J. Costa-Pinto,<br />
Amparo Vayá, Vicente Vicente, Ana G. Mauricio, José<br />
R. González-Porras, Juan Monteagudo, Ter<strong>es</strong>a Martínez-<br />
Marini, María L. Blanco, José A. Aznar, Amparo Estellés,<br />
Francisco España
C0076 THE ENDOTHELIAL PROTEIN C RECEPTOR IS ESSEN-<br />
TIAL FOR PROTEIN C ACTIVATION IN VIVO<br />
Elena Bonet, Pilar Medina, Silvia Navarro, Laura Martos,<br />
Amparo Estellés, Rogier M. Bertina, Francisco España<br />
11:15-11:45 Coffee Break<br />
11:45-13:00 Plenary S<strong>es</strong>sion (Auditorium Athéna)<br />
Chair: Françoise Dign<strong>at</strong>-George<br />
11:45-12:20 Wh<strong>at</strong> did we learn from new oral anticoagulant<br />
tre<strong>at</strong>ment?<br />
Charl<strong>es</strong> T. Esmon<br />
12:20-13:00 Endothelial progenitor cells and therapeutic<br />
angiogen<strong>es</strong>is<br />
Jean-Sébastien Silv<strong>es</strong>tre<br />
13:00-14:00 Posters s<strong>es</strong>sion (PS3) (Foyer)<br />
14:00-15:30 Oral Communic<strong>at</strong>ions (CO13, CO14, CO15)<br />
CO13: Women’s Health (Auditorium Athéna)<br />
Chair: Jacqueline Conard<br />
C0284 DOES A TIGHT FIBRIN CLOT IN PREMENOPAUSAL<br />
WOMEN WITH TYPE 1 DIABETES EXPLAIN THE<br />
LACK OF GENDER DIFFERENCE IN CARDIOVASCU-<br />
LAR DISEASE?<br />
Aleksandra Antovic, Nils Håkan Wallèn, Graciela Elgue,<br />
Koteiba Majeed, Peter Henriksson, Anna Ågren, Ulf Adamson,<br />
Per-Eric Lins, Gun Jörn<strong>es</strong>kog<br />
C0298 DIFFERENTIAL RISK FACTORS FOR PREGNANCY<br />
RELATED DEEP VEIN THROMBOSIS AND PULMO-<br />
NARY EMBOLISM - RESULTS FROM A POPULATION-<br />
BASED CASE-CONTROL STUDY<br />
Astrid Bergrem, Anders E.A. Dahm, Anne Flem Jacobsen,<br />
Leiv Sandvik, Per Morten Sandset<br />
C0355 PREGNANCY RELATED THROMBOSIS RISK IN PA-<br />
TIENTS WITH PROTEIN C DEFICIENCY<br />
Rugeri Lucia, Khou<strong>at</strong>ra Linda, Arnuti Brigitte, Trzeciak<br />
Marie-Christine, Dargaud Y<strong>es</strong>im<br />
C0380 LONG-TERM IMPACT OF VENOUS THROMBOSIS ON<br />
QUALITY OF LIFE, GENERAL HEALTH AND FUNC-<br />
TIONING: A CROSS-SECTIONAL, CASE-CONTROL<br />
STUDY<br />
Hilde Skuterud Wik, Anne Flem Jacobsen, Leiv Sandvik,<br />
Per Morten Sandset<br />
C0385 MORTALITY AFTER PREGNANCY-RELATED VENOUS<br />
THROMBOSIS<br />
Hilde Skuterud Wik, Anne Flem Jacobsen, Leiv Sandvik,<br />
Per Morten Sandset<br />
C0167 PREGNANCY AND LABOR IN PATIENTS WITH HIS-<br />
TORY OF ISCHEMIC STROKE.<br />
Alexander Mak<strong>at</strong>sariya, Viktoriya Bitsadze, Dzhamilya<br />
Khizroeva, Svetlana Akinshina<br />
CO14: Thrombophilia (Auditorium Hermès)<br />
Chairs: Turgut Ulutin and Ulrich Abildgaard<br />
C0229 REGULATORY REGIONS OF SERPINC1 GENE: IDEN-<br />
TIFICATION OF THE FIRST MUTATION ASSOCIATED<br />
WITH ANTITHROMBIN DEFICIENCY.<br />
María Eugenia de la Morena-Barrio, Ana Isabel Antón,<br />
Irene Martínez-Martínez, Jose Padilla, Antonia Miñano,<br />
Jose Navarro-Fernández, Sonia Águila, María Fernanda<br />
López, Jordi Fontcuberta, Vicente Vicente, Javier Corral<br />
C0075 TYPE II ANTITHROMBIN DEFICIENCY CAUSED BY<br />
A LARGE IN-FRAME INSERTION. STRUCTURAL,<br />
FUNCTIONAL AND PATHOLOGICAL RELEVANCE.<br />
Irene Martínez-Martínez, Daniel J.D. Johnson, Masayuki<br />
Yamasaki, José Navarro-Fernández, Adriana Ordóñez,<br />
Vicente Vicente, Jam<strong>es</strong> A. Huntington, Javier Corral<br />
C0094 HIGH INCIDENCE OF COMPOUND HETEROZYGO-<br />
SITY IN ANTITHROMBIN DEFICIENCY: DIAGNOSTIC<br />
AND PROGNOSTIC RELEVANCE.<br />
Sonia Aguila, Irene Martínez-Martínez, Miriam Collado,<br />
Pilar Llamas, Antonia Miñano, Ana Isabel Antón, María Eugenia<br />
de la Morena-Barrio, Vicente Vicente, Javier Corral<br />
C0176 INFLUENCE OF COMMON THROMBOPHILIA POLY-<br />
MORPHISMS ON THE THROMBOSIS RISK IN PA-<br />
TIENTS WITH JAK2-V617F-POSITIVE MYELOPRO-<br />
LIFERATIVE NEOPLASMS<br />
Vangelis Giamouris, Mariana Befani, Emanouil Papadakis,<br />
Eudokia Mandala, Nikolaos Papadoulis, Spyros<br />
Karamagiolis, Vassiliki Gastari, Eugenia Verrou, Eirini K<strong>at</strong>odritou,<br />
Stelios Lafioni<strong>at</strong>is, Zafiris Kartasis, Konstantinos<br />
Magiannis, Paulina Marinaki, Konstantina Tsioni, Anna<br />
Kioumi, Anastasios E. Germenis, M<strong>at</strong>thaios Speletas<br />
C0372 ENHANCED THROMBIN GENERATION IN WOMEN<br />
WITH HISTORY OF ORAL CONTRACEPTION RELAT-<br />
ED VENOUS THROMBOSIS<br />
Saša Anžej Doma, Maja Vučnik, Mojca Božič Mijovski,<br />
Polona Peternel, Mojca Stegnar<br />
C0430 IS THE PRESENCE OF THE MUTATION OF FXIII A KEY<br />
OF EPIGENETIC IMPACT IN THE EXPRESSION OF<br />
THROMBOPHILIC PREDISPOSITION?<br />
Makris Pantelis, Pagourelias E., Makris MP., Papadopoulou<br />
AA., Giannoglou G.<br />
CO15: Antipl<strong>at</strong>elets agents (Auditorium Rhod<strong>es</strong>)<br />
Chairs: Thomas Lecompte and Juana Vall<strong>es</strong><br />
C0231 PATIENTS PRESENTING WITH AN ACUTE CORO-<br />
NARY SYNDROME WHILE ON CHRONIC ASPIRIN<br />
TREATMENT: DO THEY REQUIRE A LOADING DOSE<br />
OF ASPIRIN ?<br />
Isabel Madrid, Antonio Moscardo, Juana Vall<strong>es</strong>, Miguel<br />
Ruano, Juan Bonastre, Ana Maria L<strong>at</strong>orre, Maria Ter<strong>es</strong>a<br />
Santos<br />
C0258 IMPORTANCE OF THE EFFECT OF ASPIRIN IN PA-<br />
TIENTS WITH ACUTE CORONARY SYNDROME<br />
WHO HAVE AN ADEQUATE ANTIPLATELET EFFECT<br />
OF CLOPIDOGREL.<br />
Isabel Madrid, Antonio Moscardo, Juana Vall<strong>es</strong>, , Juan<br />
Bonastre, Miguel Ruano, Ana L<strong>at</strong>orre, Maria Ter<strong>es</strong>a Santos<br />
C0338 CORRELATION BETWEEN PLATELET FUNCTIONAL<br />
PARAMETERS MEASURED BY IMPENDANCE AG-<br />
GREGOMETRY AND BLOOD COAGULATION MARK-<br />
ERS WITH OCCURRENCE OF MAYOR ADVERSE<br />
CARDIOVASCULAR EVENTS IN PATIENTS WITH<br />
ACUTE MYOCARDIAL INFARCTION TREATED WITH<br />
PRIMARY PERCUTANEOUS<br />
Tina Kocica, Nebojsa Antonijevic, Nebojsa Savic, Lazar<br />
Davidovic<br />
C0278 COMPARATIVE EFFECTIVENESS OF DIFFERENT<br />
DOSES ANTIPLATELET THERAPY AND FORMS ACE-<br />
TYLSALICYLIC ACID IN PATIENTS WITH STABLE AN-<br />
GINA<br />
Oksana Demyanenko, Valeriy Vishnevskiy<br />
C0279 HYPERCHOLESTEROLEMIA - A RESISTANCE FAC-<br />
TOR IN ANTIPLATELET THERAPY<br />
Valeriy Vishnevskiy, Oksana Demyanenko<br />
16:00 End of the Congr<strong>es</strong>s
Poster S<strong>es</strong>sion<br />
17:50-18:30 Posters S<strong>es</strong>sion (PS1) (Foyer)<br />
P0018 NEW MUTATION SS => 125 IN DVT<br />
Jean-François Schved<br />
P0024 NICOTINIC ACID/LAROPIPRANT ADDITION TO CHRONIC LIPID<br />
APHERESIS IN VERY HIGH-RISK PATIENTS WITH ACUTE CORONARY<br />
SYNDROMES.<br />
Gabriele Cioni, Rossella Marcucci, Lucia Mannini, Sandra Fedi,<br />
Stefano Bucci, Alfredo Sab<strong>at</strong>o, Rosanna Abb<strong>at</strong>e, Giovanna D’Al<strong>es</strong>sandri<br />
P0028 EFFICACY AND SAFETY KOAGIL-VII (JSC “PHARMSTANDARD”)<br />
ADMINISTRATION AFTER CARDIAC SURGERY IN PATIENTS WITH<br />
HIGH BLEEDING RISK<br />
Galina V. Lobacheva, Mikhail M. Rybka, N<strong>at</strong>alia N. Samsonova,<br />
Elena F. Kozar<br />
P0050 EPLERENONE, A NEW SELECTIVE MINERALOCORTICOID RECEPTOR<br />
ANTAGONIST, INHIBITS PLATELET ADHESION AND ATTENUATES<br />
ENDOTHELIAL DAMAGE IN ARTERIAL THROMBOSIS MODEL IN<br />
DIABETIC RATS.<br />
Ewa Chabielska, Urszula Bycul, Agni<strong>es</strong>zka Zakrz<strong>es</strong>ka, Piotr Szoka,<br />
Wioleta Kisiel, Irena Kasacka<br />
P0064 ADRENAL GLAND-DEPENDENT PROCESS OF ARTERIAL THROMBUS<br />
FORMATION IN DIABETIC RATS<br />
Piotr Szoka, Agni<strong>es</strong>zka Zakrz<strong>es</strong>ka, Urszula Bycul, Wioleta Kisiel, Irena<br />
Kasacka, Ewa Chabielska<br />
P0065 WHITE BLOOD CELL COUNT MEASURED PRIOR TO CANCER<br />
DEVELOPMENT IS ASSOCIATED WITH FUTURE RISK OF VENOUS<br />
THROMBOEMBOLISM IN CANCER PATIENTS – THE TROMSØ STUDY<br />
Hilde Jensvoll, Kristine Blix, Sigrid Brækkan, John-Bjarne Hansen<br />
P0084 THE EFFECT OF CME EDUCATIONAL PROGRAMS ON VTE MORALITY &<br />
MORBIDITY IN KING FAHAD HOSPITAL – JEDDAH –KSA<br />
Essam AboElNazar, Fahd Alhameed<br />
P0088 DIFFERENTIAL ASSOCIATIONS BETWEEN EDUCATIONAL LEVEL AND<br />
FUTURE RISK OF VENOUS THROMBOEMBOSLISM AND MYOCARDIAL<br />
INFARCTION. THE TROMSØ STUDY.<br />
Kristin F. Enga, Knut Gjelland, Sigrid K. Brækkan, John-Bjarne<br />
Hansen<br />
P0092 PREDICTIVE FACTORS FOR VENOUS RECANALISATION AFTER FIRST<br />
IDIOPATHIC VENOUS THROMBOSIS<br />
Tjasa Vizintin-Cuderman, Monika Stalc, Alenka Mavri<br />
P0093 HEMATOCRIT MEASURED PRIOR TO CANCER DEVELOPMENT IS NOT<br />
ASSOCIATED WITH FUTURE RISK OF VENOUS THROMBOEMBOLISM<br />
IN CANCER PATIENTS – THE TROMSØ STUDY<br />
Hilde Jensvoll, Kristine Blix, Sigrid Brækkan, John-Bjarne Hansen<br />
P0103 MEDITERRANEAN PARADOX: DOES IT EXIST IN VENOUS<br />
THROMBOEMBOLIC DISEASE<br />
Juan Francisco Sanchez Muñoz-Torrero, Alicia Lorenzo<br />
Hernández, Javier Trujillo<br />
P0104 EVOLUTION OF VENOUS THROMBOEMBOLIC DISEASE IN PATIENTS<br />
WITH DIABETES: RISK OR PROTECTOR FACTOR?<br />
Alicia Lorenzo Hernández, Maria Del Carmen Fernández<br />
Capitán, Sarah Caro Bragado, Maria De Los Angel<strong>es</strong> Rodriguez Dávila,<br />
Mikel Rico Briñas, Maria Fernández Velilla, Maria Cu<strong>es</strong>ta, Maria Isabel<br />
Torr<strong>es</strong> Sánchez<br />
P0105 DIABETIC PATIENTS AND VENOUS THROMBOEMBOLIC DISEASE. IS<br />
THERE ANY DIFFERENCE?<br />
María Del Carmen Fernández Capitán, Alicia Lorenzo Hernández,<br />
Sarah Caro Bragado, María Angel<strong>es</strong> Rodriguez Dávila, Mikel Rico Briñas,<br />
Marina Triguero Genao, María Fernández Velilla, María Osabel Torr<strong>es</strong>,<br />
María Isabel Torr<strong>es</strong><br />
P0106 DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM: SAME<br />
DISEASE IN DIABETIC PATIENTS?<br />
Alicia Lorenzo Hernández, María Del Carmen Fernández<br />
Capitán, Juan Francisco Sánchez Muñoz-Torrero, Mikel Rico Briñas,<br />
Marina Triguero Genao, Georgina Salgueiro, María Fernández Velilla,<br />
María Isabel Torr<strong>es</strong> Sánchez, Maria Angel<strong>es</strong> Rodriguez Davila<br />
P0110 SERUM LEVELS OF VITAMIN D IS NOT ASSOCIATED WITH FUTURE<br />
RISK OF VENOUS THROMBOEMBOLISM – THE TROMSØ STUDY<br />
Ellen Brodin, Gunhild Lerstad, Guri Grimn<strong>es</strong>, Sigrid K Brækkan,<br />
Johan Svartberg, Rolf Jorde, John-Bjarne Hansen<br />
P0135 IN VITRO AND IN SILICO STUDY OF THE EFFECT OF CROCIN AND<br />
SAFRANAL ON HUMAN PLASMA COAGULATION<br />
Maria Ditsa, George Geromihalos, Eleftheria Tragoulia, Dimitra<br />
Markala, Chrisa Meleti, Zaxarias Sinakos<br />
P0144 THE COMPARISON OF TWO DIFFERENT ANTITHROMBOTIC REGIMENS<br />
IN PATIENTS WITH ATRIAL FIBRILLATION FOR THE PREVENTION OF<br />
ISHAEMIC STROKE<br />
Sladjana Novaković-Anučin, Sanja Gnip, Višnja Čanak, Pavica<br />
Radović, Milena Šćekic, Jelena Kovačev, Gorana Mitić<br />
P0145 HAEMOSTATIC SYSTEM CHANGES IN ORTHOTOPIC LIVER<br />
TRANSPLANTATION - SINGLE CENTER EXPERIENCE<br />
Sladjana Novaković-Anučin, Sanja Gnip, Višnja Čanak, Djurdjina<br />
Jurišić, Pavica Radović, Svetlana Erdeljan, Zoran Milošević,<br />
Gorana Mitić<br />
P0150 THE FEATURES OF ANTIPLATELET THERAPY IN INFLAMMATION<br />
Liudmila Buryachkovskaya, Alexander Sumarokov, Irina Uchitel<br />
P0151 THE ROLE OF P-SELECTIN IN DEEP VENOUS THROMBOSIS: A META-<br />
ANALYSIS<br />
Constantine Antonopoulos, Triantafillos Giannakopoulos,<br />
Aristeidis Kallinis, Ioannis Vasilopoulos, Ilias Dalainas, John Kakisis,<br />
Christos Liapis<br />
P0153 EVALUATION OF ATRIAL FIBRILLATION POPULATION IN APULIA<br />
REGION FOR THE COST/EFFECTIVENESS ANALYSIS FOR THE USE<br />
OF OLD AND NEW ORAL ANTICOAGULANTS: COOPERATION OF<br />
HEMATOLOGIST, CARDIOLOGIST AND INTERNIST<br />
Nicola Ciavarella, Paolo Colonna, Ennio Michelotto, Vito Lepore,<br />
Fabio Robusto, Elvira Grandone, Luigi Ria, Giacomo Lucarelli, Salv<strong>at</strong>ore<br />
Bradamante, Michele Virgilio, Gianfranco Antonelli, Pasquale Caldarola,<br />
Carlo D’Agostino, Stefano Favale, Giovanni Tognoni<br />
P0159 β1 BLOCKERS, WARFARIN AND RHYTHM CONVERSION IN ATRIAL<br />
FIBRILLATION<br />
Ruzan Durgaryan<br />
P0163 ROLE OF A3 HAPLOTYPE OF EPCR IN THE DEVELOPMENT OF DEEP<br />
VEIN THROMBOSIS IN ASIAN INDIAN.<br />
Amit Sharma, Arijit Biswas, Ravi ranjan, Mohd. Suhail Akhter, Ravi<br />
kumar, Kamal Kishor, Renu Saxena<br />
P0168 THE APCR RATIO IS DIFFERENTLY INFLUENCED BY WARFARIN<br />
THERAPY WHEN DIFFERENT ASSAYS ARE USED.<br />
Petr K<strong>es</strong>sler, Hynek Poul, Arnost Komarek, Maria Kusnierova,<br />
Michaela Harudova<br />
P0169 CAVE THROMBOSIS IN BEHçET’S DISEASE: A REPORT OF 29 CASES.<br />
Ben Ghorbel Imed, Belfeki Nabil, Said F<strong>at</strong>ma, Ben Salem<br />
Thouraya, Lamloum Mounir, Braham Amel, Khanfir Monia, Hamzaoui<br />
Amira, Houman Habib<br />
P0172 UNUSUAL COMPLICATION IN WEGENER’S GRANULOMATOSIS: DEEP<br />
VENOUS THROMBOSIS. ABOUT FOUR CASES.<br />
Ben Ghorbel Imed, Belfeki Nabil, Braham Amel, Lamloum Mounir,<br />
Ben Salem Thouraya, Khanfir Monia, Hamzaoui Amira, Houman Habib<br />
P0178 CYP2C9 AND VKORC1 GENE POLYMORPHISMS IN THE HEALTHY<br />
RUSSIAN AND BURYAT RESPONDENTS IN TRANSBAIKALIA<br />
Olga Stepanova, Marine Avetisyan, Yuri Vitkovsky
P0179 DEEP VEIN THROMBOSIS OF UPPER EXTREMITIES(UEDVT): A<br />
TERTIARY CENTER’S EXPERIENCE<br />
Anastasia Banti, Emmanouil Papadakis, Vassilios Papadopoulos,<br />
Konstantinos Loukidis, Dionysia Theocharidou, Smaragda Efraimidou,<br />
Anna Karagianni, Vaia Papageorgiou, Vassiliki Pissanidou, Parthena<br />
Kapali, Anna Kioumi<br />
P0181 THE ASSOCIATION OF FUNCTIONAL POLYMORPHISMS OF IL-6 GENE<br />
PROMOTER WITH ISCHEMIC STROKE.<br />
Mohd. Suhail Akhter, Arijit Biswas, Ravi Ranjan, Amit Sharma,<br />
kamal kishor, Renu Saxena<br />
P0183 ATYPICAL HEMOLYTIC- UREMIC SYNDROME BY DEFICIT IN MCP<br />
DIAGNOSED AT A TEENAGER<br />
Hedouas Meriem, Khedri Nassima<br />
P0185 CAN OVERALL HAEMOSTASIS POTENTIAL (OHP) DISCRIMINATE<br />
BETWEEN PATIENTS WHO WILL SUFFER EARLY RESTENOSIS AFTER<br />
FEMOROPOPLITEAL PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY<br />
(PTA) FROM THOSE WHO WILL NOT?<br />
Maja Vučnik, Vinko Boc, Aleš Blinc, M<strong>at</strong>jaž Vrtovec, Rok Perme,<br />
Barbara Krevel, M<strong>at</strong>ija Kozak, Petra Malovrh, Barbara Eržen, Mojca<br />
Božič-Mijovski, Mojca Stegnar<br />
P0186 HOMOCYSTEINE AND LP(A) IN PATIENTS WITH ISCHAEMIC<br />
CEREBROVASCULAR ACCIDENTS<br />
Aik<strong>at</strong>erini Hasiou, Michail Hasios, Paraskevi Karapavlidou,<br />
Anastasia Dimitrouli, Ioanna Passalidou<br />
P0206 EFFECTIVENESS AND SAFETY OF ARGATROBAN IN THE ACUTE<br />
TREATMENT OF DEEP VEIN THROMBOSIS IN PATIENT WITH ALLERGY<br />
TO HEPARIN UNDERGOING RENAL REPLACEMENT THERAPY: A CASE<br />
REPORT<br />
M<strong>at</strong>teo Giorgi-Pierfranc<strong>es</strong>chi, Roberto Scarpioni, Sergio<br />
Ballocchi, Vittorio Albertazzi, Stefania D’Amore, Sara De Amicis, Marco<br />
Ricardi, Piergiorgio Poisetti<br />
P0225 DIGITAL TV AND MOBILE DEVICES TO INCREASE THE COMPLIANCE/<br />
PERSISTENCE TO MEDICINES IN CHRONIC SUBJECTS ON ORAL<br />
ANTICOAGULANT DRUGS: THE PILOT STUDY<br />
Giovanni Dirienzo, Nicola Ciavarella, Lino Renna, Nicola Pansini,<br />
Michele Virgilio<br />
P0232 CURCUMIN ATTENUATES INFLAMMATORY AND THROMBOTIC<br />
EVENTS INDUCED BY REPEATED PULMONARY EXPOSURE TO DIESEL<br />
EXHAUST PARTICLES IN MICE<br />
Abderrahim Nemmar, Deepa Subramaniyan, Badreldin Ali<br />
P0239 WHICH ARE THE MOST EVIDENCE-BASED AND COST-EFFECTIVE<br />
STRATEGIES FOR TREATING PATIENTS WITH HEART FAILURE?<br />
Jennifer Creed<br />
P0287 ASSESSMENT OF ENDOTHELIAL FUNCTION BY PERIPHERAL<br />
ARTERIAL TONOMETRY IN PATIENTS WITH PREVIOUS ACUTE<br />
CORONARY SYNDROME IDENTIFIES SYSTEMIC ATHEROSCLEROSIS<br />
INDEPENDENTLY OF TRADITIONAL RISK FACTORS.<br />
Gabriele Cioni, Rossella Marcucci, Franc<strong>es</strong>ca C<strong>es</strong>ari, Serafina<br />
Valente, Cristina Giglioli, Rosanna Abb<strong>at</strong>e, Maria Boddi<br />
P0292 LIPID LEVELS AND RISK OF VENOUS THROMBOSIS<br />
Aránzazu García Raso, Raquel M<strong>at</strong>a, Rosa Vidal, Sol Sánchez, Pilar<br />
Llamas<br />
P0294 DEEP VENOUS THROMBOSIS IN PATIENTS WITH NO O- GROUP<br />
Aránzazu García Raso, Raquel M<strong>at</strong>a, Elham Askari, Claudia Gorcea,<br />
Pilar Llamas<br />
P0305 DEEP VEIN THROMBOSIS AND MALFORMATIONS OF INFERIOR VENA<br />
CAVA<br />
Ruth Calderón Hernáiz, Justo Ruiz Ruiz, Olga M<strong>at</strong>eo Rodriguez,<br />
Diego Orlando Rejas Velasquez, Elena Madroñal Cerezo, Rosa María<br />
Martín Díaz, Alicia Castro Gordon, María Fernández López, J<strong>es</strong>ús Canora<br />
Lebr<strong>at</strong>o, Antonio Zap<strong>at</strong>ero Gaviria<br />
P0307 BASELINE CHARACTERISTICS AND MANAGEMENT OF PATIENTS<br />
WITH SPLANCHNIC VEIN THROMBOSIS: RESULTS OF AN<br />
INTERNATIONAL REGISTRY<br />
Walter Ageno, Nicoletta Riva, Sam Schulman, Soo-Mee Bang, Maria<br />
Ter<strong>es</strong>a Sartori, Elvira Grandone, Jan Beyer, Giovanni Barillari, Dario Di<br />
Minno, Rita Duce, Al<strong>es</strong>sandra Mal<strong>at</strong>o, Rita Santoro, Daniela Poli, Peter<br />
Verhamme, Ida Martinelli, Pieter Kamphuisen, Adriano Al<strong>at</strong>ri, Doyeun<br />
Oh, Elbio D’Amico<br />
P0309 VENA CAVA THROMBOSIS IN BEHCET DISEASE<br />
Bellakhal Syrine, Hamzaoui Amira, Saïd F<strong>at</strong>ma, Ben Salem Thouraya,<br />
Smiti-Khanfir Monia, Braham Amel, Ben Ghorbel Imed, Lamloum<br />
Mounir, Houman Mohamed-Habib<br />
P0318 NEUROLEPTIC DRUGS AND VENOUS THROMBOEMBOLIC DISEASE<br />
María J<strong>es</strong>ús Jaras Hernández, Jose Francisco Pascual Pareja, Alicia<br />
Lorenzo Hernández, Mar M<strong>at</strong>in Pozo, José.M Luque. Pinilla,<br />
Javier Gutierrez Guisado, Olga Madridano Cobo, M.Angel<strong>es</strong> Rodriguez<br />
Dávila, Carmen Fernández Capitán<br />
P0320 ORAL ANTICOAGULATION IN ATRIAL FIBRILLATION, THE PATIENTS<br />
AND PHYSICIANS EXPERIENCES OF THE CONSULTATION; A<br />
QUALITATIVE STUDY.<br />
Christian Borg Xuereb, Rachel L. Shaw, Gregory Y.H. Lip, Deirdre<br />
A. Lane<br />
P0325 A 40 YEARS SURVEY OF PULMONARY EMBOLISM DOCUMENTED<br />
AT AUTOPSY IN A TERTIARY CARE HOSPITAL FROM CORDOBA,<br />
ARGENTINA<br />
Aldo Hugo Tabar<strong>es</strong>, Romina Montivero, Rosio Baena Terán, Carina<br />
Seculini, Andr<strong>es</strong> Arancibia, Luciana Guanchiale, Ana Diller, Juan García<br />
P0335 VITAMIN K ANTAGONISTS TREATMENT AND ENDOGENOUS<br />
THROMBIN POTENTIAL IN PATIENTS WITH VENOUS<br />
THROMBOEMBOLISM.<br />
Veronika Shmeleva, Yriy Nam<strong>es</strong>tnikov, Ol<strong>es</strong>ya M<strong>at</strong>vienko, Vitaly<br />
Sold<strong>at</strong>enkov<br />
P0336 VENOUS THROMBOEMBOLISM (VTE) AT RARE SITES IN NEONATES<br />
AND CHILDREN<br />
Pergantou Helen, Avgeri Maria, Komitopoulou Anna, Xafaki<br />
Panagiota, Kapsimali Zoey, Karelioti Helen, Pl<strong>at</strong>okouki Helen<br />
P0359 CHARACTERISTICS OF DEEP VENOUS THROMBOSIS IN TUNISIAN<br />
BEHçET’S DISEASE PATIENTS<br />
Bellakhal Syrine, Saïd F<strong>at</strong>ma, Ben Salem Thouraya, Hamzaoui Amira,<br />
Braham-Sfaxi Amel, Smiti-Khanfir Monia, Ben Ghorbel Imed, Lamloum<br />
Mounir, Houman Mohamed-Habib<br />
P0368 A FEVERISH LUMBAGO AT A PATIENT WITH A BEHçET’S DISEASE IN<br />
REMISSION : THINK OF THE THROMBOSIS OF THE RENAL VEIN<br />
Mounir Lamloum, Mounir Lamloum, Imène Rachdi, Imed Ben<br />
Ghorbel, Thouraya Ben Salem, Amira Hamzaoui, Monia Khanfir, Amel<br />
Braham, Mohamed Habib Houman<br />
P0370 PLASMA LEVELS OF SOLUBLE CD36, PLATELET ACTIVATION,<br />
INFLAMMATION AND OXIDATIVE STRESS ARE INCREASED IN TYPE 2<br />
DIABETIC PATIENTS<br />
Simona S<strong>es</strong>tili, Franc<strong>es</strong>ca Santilli, Bente Halvorsen, Aase Handberg,<br />
Rossella Liani, N<strong>at</strong>ale Vazzana, Gloria Formoso, Pål Aukrust, Giovanni<br />
Davì<br />
P0371 VENOUS THROMBOSIS IN AMEBIC COLITIS<br />
Mounir Lamloum, Imène Rachdi, Imed Ben Ghorbel, Amira<br />
Hamzaoui, Thouraya Ben Salem, Monia Khanfir, Amel Braham, Mohamed<br />
Habib Houman<br />
P0373 VENOUS THROMBOSIS REVEALING A CROHN’S DISEASE<br />
Mounir Lamloum, Imène Rachdi, Imed Ben Ghorbel, Amira<br />
Hamzaoui, Thouraya Ben Salem, Monia khanfir, Amel Braham, Mohamed<br />
Habib Houman<br />
P0376 VENOUS THROMBOSIS REVEALING A MULTIPLE MYELOMA<br />
Mounir Lamloum, Imène Rachdi, Imed Ben Ghorbel, Amira<br />
Hamzaoui, Thouraya Ben Salem, Monia khanfir, Amel Braham, Mohamed<br />
Habib Houman
P0389 INFLAMMATION, OXIDATIVE STRESS AND PLATELET ACTIVATION IN<br />
ASPIRIN-TREATED CRITICAL LIMB ISCHAEMIA: BENEFICIAL EFFECTS<br />
OF ILOPROST.<br />
N<strong>at</strong>ale Vazzana, Gianfranco L<strong>es</strong>siani, Chiara Cuccurullo, Dario Di<br />
Michele, Giuseppe Laurora, Giuseppe Sgrò, Paolo Di Ruscio, Emilio<br />
Simeone, Pierangelo Di Iorio, Stefano L<strong>at</strong>tanzio, Rossella Liani, Giovanni<br />
Davì<br />
P0392 CANCER-ASSOCIATED THROMBOSIS; A STUDY OF 806 CASES OF<br />
DEEP VENOUS THROMBOSIS<br />
Smiti Khanfir Monia, Bellakhal Syrine, Hamzaoui Amira, Ben Salem<br />
Thouraya, Braham Amel, Ben Ghorbel Imed, Lamloum Mounir,<br />
Houman Mohamed Habib<br />
P0393 RISK FACTORS AND PREVALENCE OF VENOUS THROMBOEMBOLISM<br />
IN INTERNAL MEDICINE: A RETROSPECTIVE STUDY OF 806 PATIENTS<br />
Bellakhal Syrine, Smiti Khanfir Monia, Hamzaoui Amira, Said F<strong>at</strong>ma, Ben<br />
Salem Thouraya, Braham Amel, Lamloum Mounir, Ben Ghorbel Imed,<br />
Houman Mohamed Habib<br />
P0395 HYPERHOMOCYSTEINEMIA, THROMBOSIS AND PERNICIOUS<br />
ANEMIA. FOUR NEW CASES.<br />
Tazi Mezalek Zoubida, Ammouri Wafaa, Harmouche Hicham,<br />
Maamar Mouna, Adnaoui Mohamed, Aouni Mohamed<br />
P0396 VENOUS THROMBOSIS REVEALING CELIAC DISEASE. THREE CASES.<br />
Tazi Mezalek Zoubida, Benecer Alaoui Habiba, Harmouche<br />
Hicham, Bachir Houda, Maamar Mouna, Adnaoui Mohamed, Aouni<br />
Mohamed<br />
P0397 THROMBOEMBOLITIC EVENTS IN PATIENTS WITH SYSTEMIC<br />
VASCULITIS<br />
Bellakhal Syrine, Hamzaoui Amira, Hajji Raouf, Smiti-Khanfir Monia,<br />
Ben Salem Thouraya, Braham-Sfaxi Amel, Ben Ghorbel Imed, Lamloum<br />
Mounir, Houman Mohamed-Habib<br />
P0408 CASE REPORT: ORAL CONTRACEPTIVES, THROMBOPHILIAS AND DEEP<br />
VEIN THROMBOSIS IN YOUNG WOMEN AFTER TONSILLECTOMY<br />
Tiha Vucemilo, Marija Skoko, Deana Sturm<br />
P0409 PREVALENCE OF ATRIAL FIBRILLATION IN PATIENTS PRESENTING<br />
WITH STROKE<br />
Uchenna Ozo, Khalil Peroo, Gemma Fitzp<strong>at</strong>rick, Khalil Kawafi<br />
P0418 USE OF THROMBOPOIETIN MIMETICS IN ACUTE ITP<br />
Ashwini Arumugaswamy, Simon He, Hang Quach, Andrew Grigg<br />
P0426 ENDOTHELIAL PROTEIN C RECEPTOR GENE POLYMORPHISMS AND<br />
RISK OF VENOUS THROMBOSIS IN YOUNG PATIENTS<br />
Georgia Anastasiou, Argyri Gialeraki, Eufrossyni Merkouri,<br />
Loukianos Rallidis, Anthi Travlou<br />
P0428 VISUALIZATION OF THE PLATELET FUNCTION<br />
Makris Pantelis, Makris Michael<br />
12:45-13:45 Posters s<strong>es</strong>sion (PS2) (Foyer)<br />
P0079 TF/TFPI IN CHRONIC MYELOPROLIFERATIVE DISORDERS.<br />
Danuta Rosc, K<strong>at</strong>arzyna Stankowska, Joanna Boinska, Grazyna<br />
Gadomska, Ewa Zekanowska, Wojciech Swistek<br />
P0095 CIRCULATING ENDOTHELIAL CELLS AND MICROPARTICLES AS<br />
PROGNOSTIC MARKERS IN ADVANCED NON-SMALL-CELL LUNG<br />
CANCER<br />
Tania Fleitas, Vicenta Martínez-Sal<strong>es</strong>, Virtud<strong>es</strong> Vila, Edelmiro<br />
Reganon, David M<strong>es</strong>ado, María Martín, José Gómez-Codina, Joaquín<br />
Montalar, Gaspar Reynés<br />
P0097 MICROPARTICLES AND MARKERS OF COAGULATION, INFLAMMATION<br />
AND ANGIOGENESIS IN PATIENTS WITH GLIOBLASTOMA BEFORE<br />
AND AFTER TREATMENT WITH TEMOZOLOMIDE AND RADIATION<br />
THERAPY: PROGNOSTIC VALUE<br />
Virtud<strong>es</strong> Vila, Gaspar Reynés, Tania Fleitas, María Martín, Edelmiro<br />
Reganon, Vicenta Martínez-Sal<strong>es</strong><br />
P0098 HIGH LEVELS OF MICROPARTICLES AND MARKERS OF COAGULATION<br />
AND INFLAMMATION DISTINGUISH DECOMPENSATED HEART<br />
FAILURE VS TO STABLE PHASE.<br />
Virtud<strong>es</strong> Vila, Ignacio Sánchez-Lázaro, Luis Almenar, Vicenta<br />
Martínez-Sal<strong>es</strong><br />
P0099 KINETICS AND MECHANISM OF INHIBITION BY ANGIOSTATIN OF<br />
PLASMINOGEN ACTIVATION UNDER THE ACTION OF UROKINASE<br />
AND TISSUE PLASMINOGEN ACTIVATOR<br />
Lilia Mukhametova, Roza Aisina, Karina Gershkovich, Dmitrii<br />
Gulin<br />
P0100 THE CONTRIBUTION OF FIBRINOLYSIS IMPAIRMENT TO THE<br />
DEVELOPMENT ON THROMBOSIS IN ANTIPHOSPHOLIPID SYNDROME<br />
(APS)<br />
Roza Aisina, Lilia Mukhametova, T<strong>at</strong>iana R<strong>es</strong>hetnyak, Ek<strong>at</strong>erina<br />
Ostryakova, N Seredavkina, N P<strong>at</strong>rusheva, Lev P<strong>at</strong>rushev, Dmitrii Gulin,<br />
Karina Gershkovich<br />
P0118 DIAGNOSTIC DIFFICULTIES FOR THE DETECTION OF LUPUS<br />
ANTICOAGULANT: EXPERIENCE OF THE HEMATOLOGY LABORATORY<br />
AT CHARLES NICOLLE HOSPITAL OF TUNIS.<br />
Ben Said Mehdi, Kallel Hajer, Chaker Farah, Ellouze Rym, Guermazi<br />
Sami<br />
P0119 THERAPEUTIC APPROACH TO VENOUS PARANEOPLASTIC<br />
THROMBOEMBOLISM. EXPERIENCE FROM A SINGLE CENTER<br />
Irene García-Cadenas, Amparo Santamaria, Jordi Fontcuberta<br />
P0120 THROMBOEMBOLIC EVENTS IN ONCOLOGICAL PATIENTS: A SINGLE<br />
CENTER EXPERIENCE.<br />
Irene García-Cadenas, Amparo Santamaria, Jordi Fontcuberta<br />
P0124 ASSESSMENT OF RISK FACTORS FOR VENOUS THROMBOEMBOLISM<br />
IN WOMEN WITH BREAST CARCINOMA<br />
Zeljko Kovac, Mirjana Kovac, Valentina Djordjevic, Zorica<br />
Tomasevic, Iva Pruner, Dragica Radojkovic<br />
P0132 INVESTIGATING ANTIPLATELET ACTIVITY OF RED AND WHITE WINE<br />
Eleftheria Tragoulia, Maria Ditsa, Chrisa Meleti, K<strong>at</strong>erina Mparmpouti,<br />
Dimitra Markala<br />
P0134 INTERNET BASED QUESTIONNAIRE FOR THE ANALYSIS OF<br />
PREFERENCE OF PATIENTS FOR ANTICOAGULANTS<br />
Zolfaghari Shabnam, Marx Svetlana, Abou Ayash Nadja, Kremer<br />
Christophe, Hoeing Vera, Schirk k<strong>at</strong>rin, Weiss Christel, Frölich Lutz,<br />
Harenberg Job<br />
P0137 XAMOS: A LARGE NON-INTERVENTIONAL STUDY IN PATIENTS<br />
UNDERGOING MAJOR HIP OR KNEE REPLACEMENT SURGERY AND<br />
RECEIVING ORAL RIVAROXABAN OR CONVENTIONAL REGIMENS<br />
FOR THROMBOPROPHYLAXIS<br />
Sylvia Haas, Alexander GG Turpie, Waheed Jamal, André Schmidt,<br />
Michael Rud Lassen, Lorenzo Mantovani, Reinhold Kreutz<br />
P0138 UTILIZATION OF WAVEFORM ANALYSIS OF ACTIVATED PARTIAL<br />
THROMBOPLASTIN TIME (APTT)- CLINICAL AND PROGNOSTIC<br />
VALUE.<br />
Eleftheria Tragoulia, Maria Ditsa, Poly Kazila, Chrisa Meleti,<br />
Anastasia Mpanti, Efi Yannaki, Dimitra Markala<br />
P0141 RADIOTHERAPY AND PLATELETS ACTIVATION IN PATIENTS WITH<br />
PROSTATE CANCER<br />
Ewa Zekanowska, Danuta Rystok-Grabska, Tomasz Wisniewski,<br />
Ewa Ziółkowska, Artur Słomka, Paulina Giemza-Kucharska, Danuta Rosc<br />
P0148 PLATELETS COXSACKIE ADENOVIRUS RECEPTOR (CAR) IN NORMAL<br />
AND INFLAMMATORY CARDIAC PATHOLOGY.<br />
Elena Gupalo, Liudmila Buryachkovskaya, Pyotr Chumachenko,<br />
N<strong>at</strong>alia Mironova<br />
P0161 LYMPHOCYTE-PLATELET ADHESION IN PATIENTS WITH CHRONIC<br />
BRAIN ISCHEMIA, CARRIED IL-10 (G-1082A), IL-10 (C-819T)<br />
POLYMORPHISMS<br />
Anna Knyazeva, N<strong>at</strong>aliya Strambovskaya, Yuri Vitkovsky<br />
P0162 ANALYSIS OF THE USE OF FIBRINOGEN TO TREAT ACQUIRED<br />
COAGULOPATHIES IN A PORTUGUESE HOSPITAL<br />
Jorge Martinez, P<strong>at</strong>ricia Amantegui, João Ribeiro, Inês<br />
Eusébio, Rita Moras, Rita Oliveira, Olímpia Fonseca, Ana<br />
Ramalhinho<br />
P0164 CLINICAL CASE REPORT: PATIENT WITH SEVERE POSTPARTUM<br />
HEMORRAGHE TREATED WITH HIGH DOSES OF FIBRINOGEN<br />
CONCENTRATE<br />
Jorge Martinez, P<strong>at</strong>ricia Amantegui, João Ribeiro, Inês Eusébio,<br />
Rita Moras, Rita Oliveira, Olímpia Fonseca, Ana Ramalhinho
P0165 CEREBRAL VENOUS THROMBOSIS AND PAROXYSMAL NOCTURNAL<br />
HEMOGLOBINURIA: A SERIES OF 12 CASES<br />
Meppiel Elodie, Crassard Isabelle, Peffault De L<strong>at</strong>our<br />
Régis, Chabri<strong>at</strong> Hugu<strong>es</strong>, Socie Gérard, Bousser Marie-<br />
Germaine<br />
P0173 HIGH LEVELS OF VON WILLEBRAND FACTOR ANTIGEN AND<br />
PROCOAGULANT FACTOR VIII FOUND IN MULTIPLE MYELOMA<br />
PATIENTS ARE ASSOCIATED WITH ACTIVITY STATUS<br />
Juraj Sokol, Emília Flochová, Juraj Chudej, Radoslava<br />
Šimonová, Daniela Chudá, Peter Chudý, Ján Staško,<br />
Peter Kubisz<br />
P0177 THE PARTICIPATION OF GAMMA/DELTA AND ALFA/BETA T-<br />
LYMPHOCYTES IN COAGREGATES FORMING WITH PLATELETS<br />
Alexey Solpov, Petr Ter<strong>es</strong>hkov, Yuri Vitkovsky<br />
P0184 THE ANALYSIS OF CELL IMAGE OF PLATELETS IN VENOUS BLOOD OF<br />
PATIENTS WITH IDEOPATHIC TROMBOCYTOPENIC PURPURA<br />
Irina S. Kastrikina, Gennady I. Kozinets, Valery M.<br />
Pogorelov, Lidiya G. Kovaleva, Elena I. Pustovaya, Marem<br />
I. Chanieva, Svetlana N. Bytchkova<br />
P0191 ACUTE MYOCARDIAL INFARCTION AND NATURAL COAGULATION<br />
INHIBITORS<br />
Michail Hasios, Aik<strong>at</strong>erini Hasiou, Paraskevi<br />
Karapavlidou, Ioanna Passalidou<br />
P0194 A NEW ORAL ANTICOAGULANT (DABIGATRAN ETEXILATE):<br />
AVAILABILITY OF LABORATORY MONITORING<br />
Vladimir Sukhanov, Olga Petrova<br />
P0197 EVALUATION OF BLEEDING SYMPTOMS IN CASE OF INHERITED FVII<br />
DEFICIENCY: ABOUT 9 CASES<br />
Ben Lakhal F<strong>at</strong>ma, El Borgi Wijdene, Ben Salah Naouel, Zahra<br />
Kaouther, Meddeb Balkis, Hafsia Raouf, Gouider Emna<br />
P0200 CLINICAL AND BIOLOGICAL FEATURES OF VON WILLEBRAND<br />
DISEASE TYPE 3: REPORT OF A TUNISIAN SERIES.<br />
Ben Lakhal F<strong>at</strong>ma, El Borgi Wijdene, Ben Salah Naouel, Zahra<br />
Kaouther, Zorguan Moez, Meddeb Balkis, Hafsia Raouf, Gouider Emna<br />
P0204 FACTOR XIII DEFICIENCY: A FAMILY REPORT<br />
Ben Lakhal F<strong>at</strong>ma, El Borgi Wijdene, Ben Salah Naouel, Zahra<br />
Kaouther, Zorguan Moez, Mahmoudi Hajer, Meddeb Balkis, Hafsia Raouf,<br />
Gouider Emna<br />
P0205 SEVERE THROMBOTIC EVENTS IN YOUNG PATIENTS WITH<br />
ANTIPHOSPHOLIPID SYNDROME<br />
Florencia Sundberg, Graciela Pedreira<br />
P0215 THE OCCURRENCE OF THROMBO-HAEMORAGIC EVENTS IN<br />
PATIENTS WITH POLYCYTHAEMIA VERA AND ESSENTIAL<br />
THROMBOCYTHAEMIA IN RELATIONSHIP TO PRESENTATION OF<br />
JAK2V617F MUTATION.<br />
Zuzana Jedinakova, Jan Stasko, Daniela Chuda, Juraj Marcinek,<br />
T<strong>at</strong>iana Burjanivova, Juraj Sokol, Peter Kubisz<br />
P0219 INHERITED FACTOR XI DEFICIENCY: A REPORT OF 11 CASES AND<br />
REVIEW OF LITERATURE<br />
Elborgi Wijdene, Ben Lakhal F<strong>at</strong>ma, Ben Salah Naouel, Zahra<br />
Kaouther, Zorguan Moez, Meddeb Balkis, Hafsia Raouf, Gouider Emna<br />
P0220 INCIDENCE OF HEMOPHILIA IN THE NORTH OF TUNISIA<br />
Elborgi Wijdene, Ben Lakhal F<strong>at</strong>ma, Ben Salah Naouel, Zahra<br />
Kaouther, Zorguan Moez, Meddeb Balkis, Hafsia Raouf, Gouider Emna<br />
P0236 PRE-ANALYTICAL CONDITIONS OF CENTRIFUGATION AND FREEZING<br />
BUT NOT TEMPERATURE AFFECT MP LEVELS<br />
Virtud<strong>es</strong> Vila, Silvia Navarro, Verónica Sánchez-López, Remedios<br />
Otero, Vicenta Martínez-Sal<strong>es</strong><br />
P0248 MPTP-DEPENDENT AND -INDEPENDENT MECHANISMS OF PLATELET<br />
APOPTOSIS: EFFECTS OF CYCLOSPORIN A<br />
Valery Leytin, Armen Gyulkhandanyan, Asuman Mutlu, Sergiy<br />
Mykhaylov, David Allen, John Freedman<br />
P0249 ELASTASE-MEDIATED FIBRINOLYSIS IN DISSEMINATED<br />
INTRAVASCULAR COAGULATION (DIC) ASSOCIATED WITH SEPSIS<br />
Tak<strong>es</strong>hi Wada, S<strong>at</strong>oshi Gando, Yuichiro Yanagida, Shinji Uegaki,<br />
Nobuhiko Kubota, Mineji Hayakawa, Atsushi Sawamura, Subrina J<strong>es</strong>min<br />
P0257 RITUXIMAB IN REFRACTORY ANTIPHOSPHOLIPID SYNDROME<br />
Abdul Kareem Almomen, Sri-Halimah Cana, Rana Hasan<strong>at</strong>o,<br />
Abdullah Abujamea<br />
P0259 THROMBIN GENERATION AND CONVENTIONAL COAGULATION<br />
MARKERS IN PATIENTS WITH HYPERCOAGULABLE STATE DUE TO<br />
LOW PT AND/OR APTT<br />
Evmorfia Papakonstantinou, Efst<strong>at</strong>hios Yfantis, Anneta<br />
Theofani, Amalia Skourbouti, Paraskevi Georgutsu, Panagiotis Safioleas,<br />
Christina Sereti, Christina Manti<br />
P0261 THROMBIN GENERATION PARAMETERS IN ACUTE MYOCARDIAL<br />
INFRACTION, MULTIPLE MYELOMA AND IN MYELOPROLIFERATIVE<br />
DISORDERS<br />
Evmorfia Papakonstantinou, Efst<strong>at</strong>hios Yfantis, Anneta<br />
Theofani, Anthi Lakoumenta, Aik<strong>at</strong>erini Lavda, Christos Pegos,<br />
Konstantinos Safioleas, Christina Manti<br />
P0264 PROTEIN Z MUTATIONS IN PATIENTS WITH FETAL LOSSES:<br />
STRUCTURAL ANALYSIS<br />
Giovanni, Luca Tiscia, Rocco Caliandro, Giovanni Nico, Valerio De<br />
Stefano, Elena Rossi, Tommaso Za, Giovanni Favuzzi, Filomena<br />
Cappucci, Lucia Fischetti, Don<strong>at</strong>ella Colaizzo, Franc<strong>es</strong>co Giuliani,<br />
Elvira Grandone<br />
P0267 GENOTYPE-PHENOTYPE RELATIONSHIP IN ITALIAN SUBJECTS WITH<br />
CONGENITAL FXI DEFICIENCY<br />
Giovanni Favuzzi, Giovanni, Luca Tiscia, Elena Chinni, Don<strong>at</strong>ella<br />
Colaizzo, Valeria Bafunno, Gennaro Vecchione, Maurizio Margaglione,<br />
Elvira Grandone<br />
P0271 PLATELETS GPIBA AND ITG A2 POLYMORPHISMS IN THE HEALTHY<br />
RUSSIAN AND BURYAT RESPONDENTS IN TRANSBAIKALIA<br />
Marine Avetisyan, Olga Stepanova, Yuri Vitkovsky<br />
P0273 CENTRAL VENOUS CATHETER-RELATED THROMBOSIS IN PATIENTS<br />
WITH ACUTE LEUKEMIA<br />
Irena Djunic, Marijana Virijevic, Aleksandra Novkovic, Nada<br />
Suvajdzic-Vukovic, Ivo Elezovic, Predrag Miljic, Ana Vidovic, N<strong>at</strong>asa<br />
Coloovic, Dragica Tomin<br />
P0274 SMOKING AND OTHER RISK FACTORIS IN PATIENTS WITH ACUTE<br />
MYOCARDIAL INFARCTION IN SOUTHERN CROATIA<br />
Duska Glavas, K<strong>at</strong>arina Novak<br />
P0277 EXPERIENCE IN THE USE OF INTRAVENOUS IMMUNOGLOBULIN<br />
IN PREGNANT WOMEN WITH RECURRENT MISCARRIAGES AND<br />
ANTIPHOSPHOLIPID SYNDROME<br />
Dina Eremeeva, Marina Zaynulina<br />
P0280 CORRELATION BEETWEEN ANNEXINV-FITC AND ANNEXIN V-V450<br />
POSITIVE MICROPARTICLES IN TWO HIGH SENSITIVITY CYTOMETERS<br />
Verónica Sánchez-López, Virtud<strong>es</strong> Vila, Vicenta Martinez-<br />
Salas, Emilia Martín-Rodriguez, Ana Mont<strong>es</strong>-Worboys, Elena Arellano,<br />
Ter<strong>es</strong>a Elias, Remedios Otero<br />
P0299 THROMBOSIS IN NEWBORNS AND NEONATES. UNSOLVED<br />
PROBLEMS.<br />
Eugene Roitman, Alexandr Rumyantsev, Andrey Momot,<br />
Nicolay Volodin, Maria Shnader, Maria Shnader<br />
P0300 MEASUREMENT OF RIVAROXABAN IN URINE BY A POINT OF CARE<br />
METHOD<br />
Job Harenberg, Astrid Schulze, Christina Gi<strong>es</strong>e, Sandra Krämer,<br />
Shanshan Du, Misael Schleger, Roland Krämer<br />
P0301 BLEEDING IN FOUR PATIENTS WITH EXCESSIVE RESPONSE TO<br />
DABIGATRAN: IMPLICATIONS FOR EMERGENCY SURGERY AND<br />
RESUSCITATION.<br />
Agnès Lillo-Le Louët, Martine Wolf, Michel-Meyer Samama
P0306 ACCURACY OF EMERGENCY PHYSICIAN–PERFORMED<br />
ULTRASONOGRAPHY IN THE DIAGNOSIS OF DEEP VEIN THROMBOSIS:<br />
A SYSTEMATIC REVIEW AND A META-ANALYSIS OF THE LITERATURE<br />
Fulvio Pomero, Franc<strong>es</strong>co Dentali, Valentina Borretta, M<strong>at</strong>teo<br />
Bonzini, Remo Melchio, Jam<strong>es</strong> D Douketis, Luigi M Fenoglio<br />
P0333 MANAGEMENT OF RECURRENT ABORTION IN AFIBRINOGENEMIA<br />
WOMAN<br />
Manijeh Lak<br />
P0337 HYPERHOMOCYSTEINEMIA AS MARKER OF HIGHER THROMBOTIC<br />
RISK IN PATIENTS WITH MULTIPLE MYELOMA.<br />
Veronika Shmeleva, Ec<strong>at</strong>erina Chait, Kudr<strong>at</strong> Abdulkadirov,<br />
Stanislav B<strong>es</strong>smeltsev<br />
P0342 EXPOSURE TO HYPOXIC ENVIRONMENT RESULTS IN ALTERED<br />
PLATELET PROTEOME AND REACTIVITY<br />
Tarun Tyagi, Shadab Ahmad, T<strong>at</strong>hag<strong>at</strong> Ch<strong>at</strong>terjee, Neha Gupta,<br />
Yasmin Ahmad, Shantanu Sengupta, M.Zahid Ashraf<br />
P0352 EVOLUTION OF THROMBIN GENERATION (ENDOGENOUS AND<br />
EXOGENOUS PATHWAY) IN PARALLEL WITH THE ANTI-FVIII<br />
INHIBITOR LEVEL IN A PATIENT WITH ACQUIRED HAEMOPHILIA,<br />
TREATED WITH MABTHERA. IN VITRO RESPONSE TO THE ADDITION<br />
OF NOVOSEVEN.<br />
Mazoyer Elisabeth, Guinet Céline, Duflot Sandrine, Dhote Robin,<br />
Samama Michel Meyer<br />
P0358 UNDERSTANDING RECURRENT THROMBOSIS OF ANTIPHOSPHOLIPID<br />
SYNDROME.<br />
Harberth Fernandez, Nuria Bermejo Vega, Carolina Martin<br />
Aguilera, Fernando Carnicero, F<strong>at</strong>ima Ibañez Espacio, Maria Jose Arcos<br />
Carmona, Maria Elena Bañas, Carmen Cabrera Silva, Julio Prieto, Maria<br />
Jose Garcia Blanco, Marisa Martin M<strong>at</strong>eos, Juan M. Bergua Burgu<strong>es</strong><br />
P0377 DOES FVL HAVE AN EFFECT ON LONGEVITY?<br />
Dilara F<strong>at</strong>ma Akın, Yonca Eğin, Nej<strong>at</strong> Akar<br />
P0384 SEVERE THROMBOCYTOPENIA AND METACHRONOUS DILATED<br />
SUPERFICIAL VEINS AND THROMBOSIS: INFECTION, AUTOIMMUNE<br />
DISORDER OR LGL CYTOPENIA?<br />
Efthymia Rig<strong>at</strong>ou, George P<strong>at</strong>erakis, Helen Pl<strong>at</strong>okouki, Kleoniki<br />
Roka, Georgia Avgerinou, Vassilios Papadakis, Sophia Polychronopoulou<br />
P0390 FIBRINOLYTIC ACTIVITY AND D-DIMER IN BEHçET’S DISEASE<br />
Belfeki Nabil, Smiti Khanfir Monia, Hamzaoui Amira, Ben Salem<br />
Thouraya, Baccouche Hela, Mahjoub Sonia, Ben Romdhane Neila,<br />
Houman Mohamed Habib<br />
P0391 DISSEMINATED INTRAVASCULAR COAGULATION IN FAMILIAL<br />
LYMPHOHISTIOCYTOSIS: A CYTOKIN THUNDERSTORM<br />
Daghor Abbaci Karima, Hakem Djennette, Berrah Abdelkrim<br />
P0398 DOES BUFFY COAT PREPARED FOR AUTOLOGOUS STEM CELL<br />
TRANSPLANTATION IN CANCER PATIENTS HAS PROCOAGULANT<br />
PROPERTIES? AN IN VITRO STUDY.<br />
Sidibe F<strong>at</strong>oum<strong>at</strong>a, Vassiliki Galea, Robert Françoise, Romain<br />
Marie Paule, Bernaudin Jean François, Lotz Jean Pierre, Selle Fréderique,<br />
Larghero Jerome, H<strong>at</strong>mi Mohamed, Van Dreden P<strong>at</strong>rick, Gerotziafas<br />
Grigoris, Elalamy Ismail<br />
P0400 RELATION BETWEEN THROMBOTIC SYMPTOMS AND FIBRIN<br />
GENERATION KINETICS IN PATIENTS WITH DYSFIBRINOGENEMIA<br />
Virtud<strong>es</strong> Vila, Elena M<strong>es</strong>a, S<strong>at</strong>urnino Haya, Ana Cid, Jose Antonio<br />
Aznar<br />
P0405 CAROTID ARTERY THROMBOSIS SECONDARY TO PENETRATING<br />
NECK TRAUMA<br />
Hamid Jiber<br />
P0406 THE RELATIONSHIP PLATELET GLYCOPROTEIN IIB RS 5911<br />
POLYMORPHISM AND PROGNOSTIC PARAMETERS IN FEMALE<br />
TURKISH PATIENTS WITH BREAST CANCER<br />
Ilyas Samet Ergün, Hilal Altınöz, Z Oya Uyguner, Nusret Erdoğan, Turay<br />
Yardımcı, Şermin Tetik<br />
P0407 CHICKENPOX IS NOT ALWAYS BENIGN: POSTVARICELLA PURPURA<br />
FULMINANS DUE TO ACQUIRED DEFICIENCY OF PROTEIN S<br />
M Angel<strong>es</strong> Dasi, Bienvenida Argil<strong>es</strong>, Sara Izquierdo, Magdalena<br />
Peinador<br />
P0414 WHY DO CHILDREN BLEED AND CLOT LESS THAN ADULTS?<br />
UNDERSTANDING THE MATURATION OF THE HAEMOSTATIC<br />
SYSTEM.<br />
Vera Ignj<strong>at</strong>ovic, Paul Monagle<br />
P0423 THE SONOGRAPHER AND ULTRASOUND GEL<br />
Bosler Frederic<br />
P0432 POTENTIAL TO PREVENT THROMBOSIS BY RELEASING INTRINSIC<br />
TISSUE-TYPE PLASMINOGEN ACTIVATOR BY ENZAMIN<br />
Osamu M<strong>at</strong>suo, Yukinori Tamura<br />
13:00-14:00 Posters s<strong>es</strong>sion (PS3) (Foyer)<br />
P0025 VENOUS THROMBOEMBOLISM AND FACTOR V LEIDEN: ENIGMA OR<br />
PARADOX.<br />
Francisco Gabriel, Olga Portolés, Manuel Labiós, C Rodriguez, E<br />
Cisneros, JR Vela, MJ Nuñez<br />
P0026 CONTEMPORARY PROPHYLAXIS OF POSTOPERATIVE VENOUS<br />
THROMBOEMBOLISM AND MONITORING OF EFFICACY:<br />
ACCUMULATED EXPERIENCE<br />
Arshak Vardanyan, Robert Mumladze, Evgeniy Roitman, David<br />
Dolidze, Mengkai Shieh<br />
P0027 MONDOR’S DISEASE IN YOUNG WOMAN DUE TO HEREDITARY<br />
THROMBOPHILIA<br />
Asya Gusina, Nina Gusina<br />
P0043 ASSOCIATION OF MDR-1 GENE POLYMORPHISM AND PLASMA<br />
PLATELET ACTIVATING FACTOR LEVELS IN PATIENTS WITH<br />
CORONARY ARTERY DISEASE<br />
Turgut Ulutin, Gülsel Ayaz, Bilgehan Karadağ, Gönül Kanıgür,<br />
Mehmet Güven, İlhan Onaran, Ahmet Dirican, Barış İlerigelen<br />
P0045 PROTEIN C DEFICIENCY IN A FAMILY WITH A HISTORY OF CHILDHOOD<br />
THROMBOSIS<br />
Anicee Danaee, Jayanthi Alamelu, David Bevan<br />
P0048 DETECTION AND CHARACTERIZATION OF NOVEL DOUBLE MISSENSE<br />
MUTATIONS OF SERPINC1 IN TYPE I INHERITED ANTITHROMBIN<br />
DEFICIENCY<br />
Haoyu Deng, Wei Shen, Yi Gu, JiWei Zhang, Jun Xie, YiFeng He, Lan<br />
Zhang<br />
P0049 IS SERUM URIC ACID A PREDICTOR OF NEW-ONSET DIABETES IN<br />
HYPERTENSIVE PATIENTS?<br />
Gwo-Ping Jong, Tsochiang Ma<br />
P0055 PATENT FORAMEN OVALE: A PATHWAY FOR MYOCARDIAL<br />
INFARCTION IN PREGNANT PATIENT – CASE REPORT<br />
Ene Mäeots, Merle Kadarik<br />
P0073 CLINICAL MANIFESTATION IN HEREDITARY THROMBOPHILIAS AND<br />
MANAGENEMT OF THROMBOSIS, PREGNANCY AND DELIVERY<br />
Ivo Elezovic, Darko Antic, Predrag Miljic, Mirjana Mitrovic, Valentina<br />
Djordjevic, Ljudmila Stojanovic, Olivera Markovic, Mirjana Kovac<br />
P0086 HIGH SENSITIVITY OF THE GLOBAL CIP ASSAY FOR HEREDITARY<br />
THROMBOPHILIA<br />
Orsolya Tóth, Jacqueline Conard, Hajna Losonczy, Barbara Réger,<br />
Marianne S. Andr<strong>es</strong>en, Marie-Hélene Horellou, Réka Móz<strong>es</strong>, Ulrich<br />
Abildgaard<br />
P0091 HIGH LEVELS OF D-DIMER AND PREVIOUS PROVOKED VENOUS<br />
THROMBOEMBOLISM ARE RISK FACTORS FOR RECURRENT<br />
IDIOPATHIC VENOUS THROMBOSIS<br />
Monika Stalc, Tjasa Vizintin-Cuderman, Alenka Mavri, Anja Boc<br />
P0111 ROLE OF INHERITED THROMBOPHILIA IN TUNISIAN WOMEN WITH<br />
RECURRENT PREGNANCY LOSSES<br />
Ellouze Rim, Kallel Hajer, Chaker Farah, Ben Said Mehdi, Guermazi<br />
Sami<br />
P0112 ACTIVATED PROTEIN C RESISTANCE IN TUNISIAN PATIENTS WITH<br />
THROMBOEMBOLIC COMPLICATION OR SPONTANEOUS RECURRENT<br />
MISCARRIAGE<br />
Chaker Farah, Ellouze Rim, Ben Said Mehdi, Kallel Hajer, Guermazi<br />
Sami
P0123 POLYMORPHISMS IN THE ANNEXIN A5 KOZAK SEQUENCE AND<br />
THROMBOSIS DISEASE IN TUNISIA<br />
Mezni Imen, Sfar Imen, Ellouze Rym, Ben Said Mehdi, Bahloul<br />
Abd<strong>es</strong>salem, Ben Romdhane Thouraya, Makhlouf Mouna, Ayed Jendoubi<br />
Saloua, Ben Abdallah Taieb Khaled, Guermazi Sami, Gorgi Yousr<br />
P0136 THE ARG6TRP PLASMIN INHIBITOR POLYMORPHISM: DOES THE<br />
PRESENCE OF THE TRP6PI ALLELE CONTRIBUTE TO DECREASED RISK<br />
OF MYOCARDIAL INFARCTION?<br />
Ana Bronic, Goran Ferenčak, Robert Bern<strong>at</strong>, Jasna Leniček Krleza,<br />
Jerka Dumić, Sanja Dabelić<br />
P0143 A RETROSPECTIVE STUDY OF THROMBOPHILIA TESTING REQUESTS<br />
IN A LARGE TEACHING HOSPITAL<br />
Michelle Kint, Sean Pl<strong>at</strong>ton, Daniel Hart, Peter MacCallum, Laura<br />
Green<br />
P0152 INCIDENCE OF HAEMORRHAGIC AND THROMBOEMBOLIC<br />
COMPLICATIONS IN PATIENTS WITH MECHANICAL HEART VALVE<br />
PROSTHESES TAKING LONGTERM VITAMIN K ANTAGONISTS<br />
Sanja Gnip, Sladjana Novakovic-Anucin, Visnja Canak, Pavica<br />
Radovic, Jelena Kovacev, Milena Scekic, Gorana Mitic<br />
P0154 VICINAL THIOLS ARE REQUIRED FOR ACTIVATION OF THE AVB3<br />
INTEGRIN IN ENDOTHELIAL CELLS<br />
Halszka Ponamarczuk, Izabela Papiewska-Pajak, K<strong>at</strong>arzyna Sobierajska,<br />
Maria Swi<strong>at</strong>kowska<br />
P0156 FII, TF, FV AND MTHFR GENE POLYMORPHISMS IN THE PATIENTS,<br />
DIED FROM INFLUENZA A H1N1 (2009)<br />
Antony Petrov, Olga Petrova, N<strong>at</strong>aliya Chartorizhskaya, N<strong>at</strong>aliya<br />
Strambovskaya, Yuri Vitkovsky<br />
P0157 COMPARISON OF THE INCIDENCE OF TREATMENT COMPLICATIONS<br />
OF LOW MOLECULAR WEIGHT HEPARIN USE DURING PREGNANCY<br />
IN THROMBOPHILIC AND NON-THROMBOPHILIC WOMEN<br />
Gorana Mitic, Mirjana Kovac, Aleksandra Novakov Mikic, Djurdjina<br />
Jurisic, Iva Sal<strong>at</strong>ic<br />
P0171 INTRACARDIAC THROMBUS IN BEHçET’S DISEASE : A REPORT OF 6<br />
CASES.<br />
Ben Ghorbel Imed, Said F<strong>at</strong>ma, Belakhel Syrine, Ben Salem<br />
Thouraya, Lamloum Mounir, Braham Amel, Khanfir Monia, Hamzaoui<br />
Amira, Houman Habib<br />
P0182 DYSREGULATED MICRORNAS RELATED TO ANGIOGENESIS<br />
EXPRESSION IN ENDOMETRIAL CANCER<br />
Luis Andrés Ramón, Aitana Braza-Boils, Juan Gilabert-Estellés,<br />
Juan Gilabert Aguilar, Melitina Chirivella Casanova, Francisco España<br />
Furió, Amparo Estellés Cortés<br />
P0192 EFFICACY AND SAFETY OF FONDAPARINUX IN THE TREATMENT<br />
OF PULMONARY EMBOLISM PROVOKED BY ROMIPLOSTIN: A CASE<br />
REPORT<br />
Dimitriy Arioli, Emanuele Negri, Al<strong>es</strong>sia Tieghi, Annamaria Casali,<br />
Maria Cristina Leone, Franc<strong>es</strong>ca Pileri, Franc<strong>es</strong>co Merli, Ido Iori<br />
P0199 LMWH AND MICRONIZED PROGESTERONE IN THE PREVENTION OF<br />
REPEATED OBSTETRIC COMPLICATIONS IN PATIENTS WITH MULTIPLE<br />
PREGNANCY AND THROMBOPHILIA.<br />
Viktoriya Bitsadze, N<strong>at</strong>alya Mak<strong>at</strong>sariya, Dzhamilya Khizroeva<br />
P0202 VALIDATION OF A POINT-OF-CARE INR COAGULOMETER IN INTENSIVE<br />
CARE PATIENTS NOT ON ORAL ANTICOAGULANT THERAPY<br />
Bo Joergensen, Karoline Dalgaard, Toke Ravn, Kurt Krogh Knudsen<br />
P0203 SIMPLE AND RAPID METHOD FOR DETECTION AND QUENCHING OF<br />
DXAI EFFECTS<br />
Hans-Jürgen Kolde, Ute Lange, Elke Bucha<br />
P0207 FACTOR V LEIDEN G1691 TO A MUTATION IS A PREVALENT GENETIC<br />
THROMBOTIC RISK FACTOR FOR RECURRENT PREGNANCY LOSS IN<br />
TUNISIAN PATIENTS<br />
Raida Karray-Bradai, Khemais Benhaj, Haykel Trabelsi, Mourad<br />
Chaari, Mohamed Guermazi, Choumous Kallel<br />
P0211 ACTIVATION AND BALANCE OF COAGULATION IN PREGNANT<br />
WOMEN TREATED WITH LOW-MOLECULAR WEIGHT HEPARIN,<br />
ADMINISTERED IN THERAPEUTIC OR PREVENTIVE DOSAGE<br />
Barbara Krevel, Mojca Bozic, Sasa Smid, M<strong>at</strong>ija Kozak<br />
P0214 THE INFLUENSE OF PAI-1 POLYPORFISM ON THE PLATELETS AND<br />
PROCOAGULANT PARTS OF THE MICROCOAGULATION OF THE<br />
BLOOD.<br />
Ek<strong>at</strong>erina Shel<strong>es</strong>t, Maria M<strong>at</strong>veeva, Ludmila Popova, Lev<br />
P<strong>at</strong>rushev, Igor Bokarev<br />
P0216 CYTOMETRIC ASSESSMENT OF PLATELET P-SELECTIN EXPRESSION<br />
IN PATIENTS WITH STICKY PLATELET SYNDROM.<br />
Peter Kubisz, Peter Chudy, Daniela Chuda, Lenka Bartosova, Jan<br />
Stasko<br />
P0217 LONG-TERM MANAGING THROMBOPROPHYLAXIS IN WOMEN WITH<br />
RISK PREGNANCY<br />
Rumjana Apostolovska, Ivanka Nikoloska, Violeta Dejanova,<br />
Violeta Neceva, T<strong>at</strong>jana Makarovska-Bojadzieva<br />
P0218 STICKY PLATELET SYNDROME IN A PATIENT WITH TRANSITORY<br />
ISCHEMIC ATTACK AND HER KINDREDS - CASE REPORT.<br />
Daniela Chuda, Peter Chudy, Lenka Bartosova, Ingrid Skornova, Jan<br />
Stasko, Peter Kubisz<br />
P0221 RISK FACTORS OF THROMBOSIS IN PATIENTS WITH MAY-THURNER<br />
SYNDROME – CASE REPORTS<br />
Lenka Bartosova, Ivana Plamenova, Daniela Chuda, Jan Stasko,<br />
Peter Kubisz<br />
P0222 THERAPEUTIC ANGIOGENESIS FOR CRITICAL LIMB ISCHEMIA DOWN-<br />
REGULATES PLATELET REACTIVITY.<br />
Peter Chudy, Jan Hudecek, Daniela Chuda, Lubos Hlinka, Ren<strong>at</strong>a<br />
Talapkova, Jan Stasko, Peter Kubisz<br />
P0223 BIERMER DISEASE REVEALED BY CEREBRAL VENOUS THROMBOSIS.<br />
Djameleddine Benkali, Malika Boucelma, Dalila Zemmour, Nabila<br />
Hamzaoui, Samia Lassouaoui, Nacer Ouadahi, Abdelkrim Berrah<br />
P0226 MONITORING OF HEMOSTASIS BY THROMBOELASTOMETRY IN<br />
NORMAL PREGNANCY<br />
Lukas Duraj, Juraj Sokol, Radoslava Simonova, Jan Stasko, Lenka<br />
Bartosova, Peter Chudý, Miroslav Hasko, Peter Kubisz<br />
P0230 ORAL CONTRACEPTIVES AND THROMBOPHILIA.<br />
Jan Stasko, Lenka Bartosova, Peter Chudy, Daniela Chuda, Juraj<br />
Sokol, Zuzana Jedinakova, Lukas Duraj, Peter Kubisz<br />
P0237 EXACT – EXTENDED ANTICOAGULATION TREATMENT FOR VTE: A<br />
RANDOMISED TRIAL<br />
Gail Heritage, Ellen Murray, Jayne Tullett, David Fitzmaurice<br />
P0252 THE LEVELS OF ENDOTHELIN-1 IN THE PLASMA OF PATIENTS WITH<br />
PERIPHERAL VITREORETINAL DEGENERATION<br />
Svetlana Serebrennikova, Yuri Vitkovsky<br />
P0254 THE EFFECTS OF HEMOLYSIS AND PRIMARY TUBE UNDER-FILLING<br />
ON SEVERAL HEMOSTASIS ASSAYS; AUTOMATIC DETECTION BY<br />
THE SYSMEX CS-2100I* SYSTEM<br />
Jacob de Haan, Joanne McGr<strong>at</strong>h, Eman Ali, Avis Charlton, Hugh<br />
Hoogendoorn<br />
P0268 HIGHER RISK OF IDIOPATHIC SMALL FOR GESTATIONAL AGE<br />
NEWBORNS IN ITALIAN WOMEN CARRYING THE ANNEXIN A5 M2<br />
HAPLOTYPE.<br />
Giovanni, Luca Tiscia, Don<strong>at</strong>ella Colaizzo, Giovanni Favuzzi, Giovanna<br />
D’Andrea, P<strong>at</strong>rizia Vergura, Rossana Santacroce, Maurizio Margaglione,<br />
Elvira Grandone<br />
P0272 NOVEL ROLE OF TOLL-LIKE RECEPTOR 3 IN TISSUE FACTOR<br />
ACTIVATION THROUGH ERK1/2 PATHWAY IN A MURINE MODEL OF<br />
HYPOXIA<br />
Indranil Biswas, Iti Garg, Bandana Singh, Gausal Khan<br />
P0282 THROMBOPHILIA AND PLACENTAL/CHORION ABRUPTION IN<br />
MULTIPLE PREGNANCY AFTER IVF<br />
Victoriya Bitsadze, N<strong>at</strong>aliya Mak<strong>at</strong>sariya, Olga Panfilova,<br />
Dzhamilya Khizroeva<br />
P0285 RISK FACTORS FOR TE RECURRENCE AFTER ORAL CONTRACEPTIVE<br />
ASSOCIATED THROMBOEMBOLISM.<br />
Dionysia Theocharidou, Emmanouil Papadakis, Konstantinos<br />
Tsepanis, Anastasia Banti, Anna Karagianni, Vaia Papageorgiou, Vassilios<br />
Papadopoulos, Vassiliki Pissanidou, Elissavet Georgiou, Anna Kioumi
P0291 ANALYSIS OF ABO GROUP IN WOMEN WITH RECURRENT<br />
SPONTANEOUS ABORTIONS<br />
Aránzazu García Raso, Carolina Miranda, Elham Askari, Rosa Vidal,<br />
Raquel M<strong>at</strong>a, Pilar Llamas<br />
P0293 OBSERVATIONAL STUDY ON ANTITHROMBOTIC PREVENTION IN<br />
THROMBOPHILIA AND PREGNANCY LOSS. THE OTTILIA STUDY<br />
Michela Villani, Elvira Grandone, Valerio De Stefano, Walter<br />
Ageno, Luigi Falasca, Paolo Puggina, Andrea Luigi Tranquilli, Maurizio<br />
Margaglione<br />
P0303 IMMUNOHISTOCHEMICAL EVALUATION OF THE PLACENTAL TISSUE<br />
IN WOMEN WITH THROMBOPHILIA AND MISCARRIAGE<br />
Ek<strong>at</strong>erina Kornyushina, Marina Zainulina, Irina Kostyuchek,<br />
Elena Vashukova<br />
P0311 ASSOCIATION BETWEEN PATENT FORAMEN OVALE AND<br />
CRYPTOGENIC ISCHEMIC STROKE IN PATIENTS 55 YEARS OLD OR<br />
OLDER<br />
Accass<strong>at</strong> Sandrine, Quenet Sara, Comtet Claude, Epin<strong>at</strong> Magali,<br />
Varv<strong>at</strong> Jérôme, Mismetti P<strong>at</strong>rick, Garnier Pierre<br />
P0312 ELECTRONIC ALERTS IMPROVE ADHERENCE AND ADEQUACY OF<br />
VTE PROPHYLAXIS IN A TERTIARY CARE HOSPITAL FROM CORDOBA,<br />
ARGENTINA<br />
Aldo Hugo Tabar<strong>es</strong>, Guadalupe Caballero Escuti,, María Ter<strong>es</strong>ita<br />
Cornavaca, Francisco Bernabeu, María Eugenia Garzón Oliva, Ana<br />
Soledad Vergottini, Romina Ivana Benkovic, Ricardo Arturo Albertini<br />
P0314 THE PROGRESS WAYS IN THE IMPROVEMENT OF IVF RESULTS BASED<br />
ON REVEALING HEMOSTASIS PATHOLOGY AND ITS CORRECTION<br />
Andrey Momot, Inna Lydina, Ludmila Tsyvkina, Galina Serduk,<br />
Oksana Borisova<br />
P0319 DECREASED THRESHOLD OF AGGREGATION TO LOW-DOSE<br />
EPINEPHRINE IS EVIDENCE OF “PLATELET HYPERAGGREGABILITY” IN<br />
PATIENTS WITH THROMBOSIS<br />
Chelsea Hay<strong>es</strong>, Sumire Kitahara, Oxana Tcherniantchouk<br />
P0324 CAN THE PREVIOUS THERAPEUTIC CONTROL OF THE MAIN RISK<br />
FACTORS TO CEREBROVASCULAR DISEASE INFLUENCE THE<br />
ACETYLSALICYLIC ACID-NON RESPONSIVE STATUS IN ACUTE<br />
ISCHEMIC STROKE PATIENTS?<br />
Margarida Freitas-Silva, Luciana Gonçalv<strong>es</strong>, Rui Medeiros, Jose<br />
Pedro Nun<strong>es</strong><br />
P0326 THE PREVALENCE OF CONGENITAL AND ACQUIRED THROMBOPHILIA<br />
AND HYPERHOMOCYSTEINEMIA IN WOMEN WITH REPEATED IN<br />
VITRO FERTILIZATION FAILURE.<br />
Marina Zaynulina, Marina Mirashvili<br />
P0327 THROMBOEMBOLISM PROPHYLAXIS AFTER CESAREAN SECTION<br />
(PRO-CS) TRIAL<br />
Farjah Algahtani, H<strong>es</strong>sa Al Dohami, Saud Abo-Harb<strong>es</strong>h, Abdel Galil<br />
Abdel Gader, Aamer Aleem<br />
P0330 OPTIMIZING CENTRIFUGATION CONDITIONS FOR PREPARING<br />
PLATELET CONCENTRATES<br />
Mojgan Pourmokhtar, Ebadollah Salek Moghaddam, F<strong>at</strong>emeh<br />
Abbasi, Soudabeh Banazadeh<br />
P0331 ADAMTS-13 AND THE PLATELETS ACTIVITY OF THE<br />
MICROCOAGULATION OF THE BLOOD AT THE PAI-1 POLYPORFISM.<br />
Maria M<strong>at</strong>veeva, Ek<strong>at</strong>erina Shel<strong>es</strong>t, Ludmila Popova, Lev P<strong>at</strong>rushev,<br />
Igor Bokarev<br />
P0334 INFLUENCE OF A CONTRACEPTIVE VAGINAL RING DELIVERING<br />
ETONOGESTREL AND ETHINYL ESTRADIOL AND A COMBINED<br />
ORAL CONTRACEPTIVE CONTAINING ETHINYL ESTRADIOL AND<br />
DEZOGESTREL ON COAGULATION AND PLATELET ACTIVATION.<br />
Veronika Shmeleva, Ludmila Papayan, N<strong>at</strong>alia Aganezova<br />
P0339 AN AUTOMATED ANTITHROMBIN ANTIGEN ASSAY ON<br />
INSTRUMENTATION LABORATORY ACL TOP ANALYSER<br />
Peter Cooper, Kieron Hickey, Fiona Co<strong>at</strong>h, Mike Makris<br />
P0340 AN AUTOMATED PROGRESSIVE ASSAY OF ANTITHROMBIN<br />
Peter Cooper, Kieron Hickey, Fiona Co<strong>at</strong>h, Mike Makris<br />
P0345 OBSTETRIC OUTCOMES AND THROMBOTIC RISK IN WOMEN<br />
APPROACHING ART PROCEDURES: A PROSPECTIVE COHORT STUDY.<br />
Michela Villani, Giovanni, Luca Tiscia, Franc<strong>es</strong>co Dentali, Don<strong>at</strong>ella<br />
Colaizzo, Filomena Cappucci, Lucia Fischetti, Walter Ageno, Maurizio<br />
Margaglione, Elvira Grandone<br />
P0351 IN VITRO RESPONSE OF THROMBIN GENERATION (CAT) AND FIBRIN<br />
FORMATION (ROTEM) WITH ENOXAPARIN, DABIGATRAN AND<br />
RIVAROXABAN<br />
Samama Michel Meyer, Guinet Céline, Le Flem Lena<br />
P0360 CLINICAL VALUE OF THROMBOPHILIA DIAGNOSTICS IN WOMEN<br />
WITH REPEATED IVF FAILURE<br />
Dzhamilya Khizroeva, Viktoriya Bitsadze, N<strong>at</strong>alya Mak<strong>at</strong>sariya,<br />
Nadezhda Stuleva<br />
P0364 LONG TERM TREATMENT WITH NADROPARIN DURING PREGNANCY<br />
AND POSTPARTUM BONE<br />
MINERAL DENSITY<br />
Gorana Mitic, Aleksandra Novakov Mikic, Jovanka Novakovic Paro,<br />
Dragana Popov, Sladjana Novakovic Anucin, Visnja Canak, Sanja Gnip,<br />
Dragan Spasic, Branka Kovacev Zavisic<br />
P0365 MORTALITY CLINICAL PREDICTOR FACTORS IN THE PULMONARY<br />
EMBOLISM PATIENTS<br />
Mireia Feliu Masgoret, Franc<strong>es</strong>c Marimon Cortés, Alexander<br />
Córdoba Castro, P<strong>at</strong>ricia Sahún Gómez, Jordi Merino Ribas, Sandra<br />
Parra Pérez, Raimon Ferré Vallès, Antoni Castro Salomó<br />
P0378 TIME IN THERAPEUTIC RANGE AND COMPLICATIONS OF<br />
ANTITHROMBOTIC TREATMENT<br />
Pavica Radovic, Jelena Kovacev, Sladjana Novakovic-Anucin, Sanja<br />
Gnip, Visnja Canak, Gorana Mitic<br />
P0379 SEVERAL POLYMORPHISMS IN THE ADAMTS13 GENE IN A PATIENT<br />
WITH THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)<br />
Julio C<strong>es</strong>ar Calderazzo, Ana C<strong>at</strong>alina Kempfer, Juvenal Paiva,<br />
Analia Sanchez-Luceros, Adriana Inés Woods, María Angela Lazzari<br />
P0387 THROMBOPHILIA IN SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE-<br />
CONTROL STUDY<br />
Smiti Khanfir Monia, Belfeki Nabil, Hamzaoui Amira, Ben Salem<br />
Thouraya, Mahjoub Sonia, Keddous Asma, Ben Romdhane Neila,<br />
Houman Mohamed Habib<br />
P0394 STROKE IN SICKLE CELL ANEMIA: A CASE REPORT<br />
Yurdanur Kilinç, Barbaros Şahin Karagün, Esra Pekoak, İlgen<br />
Şaşmaz<br />
P0403 PREVALENCE OF FV LEIDEN, PROTHROMBIN FII 20210G>A, PAI-1<br />
(SERPINE1) 4G/5G, GPVI 13254T>C, SERPINC1 ( IVS +141G>A) AND<br />
CYP4V2 LYS259GLN IN CZECH REPUBLIC.<br />
Jan Kvasnicka, Jaroslava Hajkova, Petra Bobcikova, Tomas<br />
Kvasnicka, Daniela Duskova, Zdenek Krska<br />
P0417 HOW WE MANAGE ANTITHROMBOTIC TREATMENT IN PREGNANCY<br />
HIGH RISK THROMBOTIC SITUATIONS:<br />
Be<strong>at</strong>riz E Grand, Maria Monica Gonzalez Alcantara, Geraldine Voto,<br />
Liliana S Voto<br />
P0420 EFFECTIVE OUTCOME OF PREGNANCIES IN CASES OF RECURRENT<br />
FETAL LOSSES<br />
A. Foifa, MP. Makris, PE. Makris<br />
P0421 PREGNANCY OUTCOMES IN WOMEN WITH INHERITED BLEEDING<br />
DISORDERS (IBD) IN A PUBLIC HOSPITAL:<br />
Be<strong>at</strong>riz E Grand, Maria Monica Gonzalez Alcantara, Guadalupe<br />
Madrid, Geraldine Voto, Liliana S Voto
Join the MLTD!<br />
Visit our booth and discover the advantag<strong>es</strong><br />
to be member of the MLTD<br />
The society aims to cre<strong>at</strong>e bridg<strong>es</strong> between clinical practice and basic<br />
science, bringing together r<strong>es</strong>earch scientists on vascular and molecular<br />
biology and clinicians of many di�erent disciplin<strong>es</strong> such as Hem<strong>at</strong>ology,<br />
Cardiology, Neurology, Angiology, Surgery, Internal Medicine, Gynecology<br />
and other disciplin<strong>es</strong> rel<strong>at</strong>ed to Thrombosis, currently the main cause of<br />
mortality in the w<strong>es</strong>tern world.<br />
The Society contribut<strong>es</strong> to the transl<strong>at</strong>ion of scienti�c advanc<strong>es</strong> to clinical<br />
practice with a multidisciplinary and intern<strong>at</strong>ional approach, organizing<br />
intern<strong>at</strong>ional congr<strong>es</strong>s<strong>es</strong> on Thrombosis, Educ<strong>at</strong>ional Cours<strong>es</strong> and Symposia<br />
oriented to the advance in the �ght against Thrombosis.<br />
- Discounted r<strong>at</strong><strong>es</strong> for Members in the biannual Intern<strong>at</strong>ional<br />
Congr<strong>es</strong>s<strong>es</strong> on Thrombosis and other scienti�c activiti<strong>es</strong> th<strong>at</strong><br />
the MLTD will organize.<br />
- Online subscription to our o�cial Journal, Thrombosis<br />
R<strong>es</strong>earch<br />
- To be nomin<strong>at</strong>ed and to receive Society and Congr<strong>es</strong>s Awards<br />
www.medleague-thrombosis.org<br />
santos_ter@gva.<strong>es</strong>{<br />
MLTD General Secretary<br />
Mª Ter<strong>es</strong>a Santos Ph. D.<br />
R<strong>es</strong>earch Center. University Hospital "La Fe"<br />
Avda Campanar, 21-<br />
46009 Valencia (SPAIN)<br />
GRUPO GEYSECO<br />
MLTD Technical Secretari<strong>at</strong><br />
Universidad, 4 -<br />
46003 Valencia (SPAIN)<br />
tel. (+34) 963 524 889 -<br />
fax. (+34) 963 942 558<br />
mltd@geyseco.<strong>es</strong>
Changing landscape in anticoagul<strong>at</strong>ion<br />
– new perspectiv<strong>es</strong> and tre<strong>at</strong>ment str<strong>at</strong>egi<strong>es</strong><br />
S<strong>at</strong>ellite Symposium<br />
The 22nd Intern<strong>at</strong>ional Congr<strong>es</strong>s<br />
on Thrombosis (ICT)<br />
Sunday, 7 October 2012 12:45-13:45<br />
‘Herm<strong>es</strong>’ room, Acropolis, Nice, France<br />
Lunch will be provided<br />
12:45 WELCOME & INTRODUCTION<br />
Chair: Prof<strong>es</strong>sor P<strong>at</strong>rick Mismetti, Saint-Etienne, France<br />
12:50 NOVEL ANTICOAGULANTS – NEW<br />
PERSPECTIVES IN ATRIAL FIBRILLATION<br />
Prof<strong>es</strong>sor José Luis Zamorano, Madrid, Spain<br />
13:05 CURRENT LANDSCAPE OF VENOUS<br />
THROMBOEMBOLISM – THE CLINICIAN’S VIEW<br />
Prof<strong>es</strong>sor P<strong>at</strong>rick Mismetti, Saint-Etienne, France<br />
13:25 NEW DIRECTIONS IN VENOUS<br />
THROMBOEMBOLISM MANAGEMENT<br />
Prof<strong>es</strong>sor Walter Ageno, Var<strong>es</strong>e, Italy<br />
13:35 PANEL DISCUSSION & MEETING CLOSE<br />
All
Gener<strong>at</strong>e Performance<br />
Stago, worldwide reference in Haemostasis<br />
• Integr<strong>at</strong>ed solutions, well known for their reliability (analysers, reagents, consumabl<strong>es</strong>)<br />
• Innov<strong>at</strong>ions d<strong>es</strong>igned to facilit<strong>at</strong>e the daily labor<strong>at</strong>ory practice<br />
• Extensive range of t<strong>es</strong>ts for both routine and r<strong>es</strong>earch settings<br />
• Performance-boosting servic<strong>es</strong> and environment (interconnectivity, technical<br />
assistance, diagnostic and accredit<strong>at</strong>ion support, EQA, training, logistics, etc.)<br />
• Recognised by the intern<strong>at</strong>ional scientific community for its expertise<br />
• Global network ensuring fast, local service in over 110 countri<strong>es</strong><br />
Diagnostica Stago S.A.S<br />
RCS Nanterre B305 151 409<br />
9, rue d<strong>es</strong> Frèr<strong>es</strong> Chausson<br />
92600 Asnièr<strong>es</strong> sur Seine (France)<br />
Ph. +33 (0)1 46 88 20 20<br />
Fax +33 (0)1 47 91 08 91<br />
webmaster@stago.com<br />
www.stago.com<br />
www.epicea.com - Photo : Shutterstock - ©2011 Diagnostica Stago - All rights r<strong>es</strong>erved - Non-contractual photos - 09/2012
01<br />
Venue Plan<br />
AUDITORIUM ATHÉNA<br />
ROOM GALLIENI 5<br />
RHODES ROOM<br />
03<br />
TECHNICAL<br />
SECRETARIAT<br />
ENTRANCE<br />
COMMERCIAL EXHIBITION<br />
POSTERS ZONE<br />
19<br />
PREVIEW ROOM<br />
AUDITORIUM HERMÉS<br />
04 05<br />
07-08<br />
09-10<br />
11- 12 13-14<br />
16<br />
18<br />
A<br />
16<br />
B<br />
C<br />
A<br />
B<br />
C<br />
INFORMATION DESK<br />
MLTD<br />
BUSINESS CENTER
Sponsor Profil<strong>es</strong><br />
BAYER HEALTHCARE<br />
Contact: Olivier Morboeuf<br />
Medical adviser<br />
E-mail:olivier.morboeuf@bayer.com<br />
Mobile: + 33 6 21 02 46 79<br />
Bayer HealthCare is among the world’s foremost innov<strong>at</strong>ors in the field of pharmaceutical and medical products. This subgroup’s mission is to<br />
r<strong>es</strong>earch, develop, manufacture and market innov<strong>at</strong>ive products th<strong>at</strong> improve the health of people and animals throughout the world.<br />
The globally oper<strong>at</strong>ing Health Care subgroup is divided into four oper<strong>at</strong>ing divisions: The goals of the Animal Health Division are to maintain the<br />
health of animals and cure veterinary diseas<strong>es</strong>, with the focus primarily on tre<strong>at</strong>ing infectious diseas<strong>es</strong> and repelling parasit<strong>es</strong>. The main focus<br />
of the Consumer Care Division is on non-pr<strong>es</strong>cription medicin<strong>es</strong> and dietary supplements. One example is Aspirin, a more than 110-year-old<br />
brand th<strong>at</strong> enjoys an unsurpassed level of global familiarity. Medical Care compris<strong>es</strong> the busin<strong>es</strong>s<strong>es</strong> with blood glucose monitoring devic<strong>es</strong> and<br />
medical equipment for diagnosis and tre<strong>at</strong>ment.<br />
The Pharmaceuticals Division is today the high<strong>es</strong>t-selling pharmaceuticals company in Germany and holds a worldwide leading position in its<br />
main therapeutic areas. The focus is on pr<strong>es</strong>cription medicin<strong>es</strong>. The division combin<strong>es</strong> its strengths in two busin<strong>es</strong>s units: General Medicine<br />
and Specialty Medicine.<br />
BOEHRINGER-INGELHEIM<br />
www.boehringer-ingelheim.com<br />
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical compani<strong>es</strong>. Headquartered in Ingelheim, Germany, it oper<strong>at</strong><strong>es</strong><br />
globally with 145 affili<strong>at</strong><strong>es</strong> and more than 44,000 employe<strong>es</strong>. Since it was founded in 1885, the family-owned company has been committed to<br />
r<strong>es</strong>earching, developing, manufacturing and marketing novel medic<strong>at</strong>ions of high therapeutic value for human and veterinary medicine.<br />
As a central element of its culture, Boehringer Ingelheim pledg<strong>es</strong> to act socially r<strong>es</strong>ponsible. Involvement in social projects, caring for employe<strong>es</strong><br />
and their famili<strong>es</strong>, and providing equal opportuniti<strong>es</strong> for all employe<strong>es</strong> form the found<strong>at</strong>ion of the global oper<strong>at</strong>ions. Mutual cooper<strong>at</strong>ion and<br />
r<strong>es</strong>pect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.<br />
In 2011, Boehringer Ingelheim achieved net sal<strong>es</strong> of about 13.2 billion euro. R&D expenditure in the busin<strong>es</strong>s area Pr<strong>es</strong>cription Medicin<strong>es</strong> corr<strong>es</strong>ponds<br />
to 23.5% of its net sal<strong>es</strong>.<br />
DAIICHI-SANKYO<br />
The Daiichi Sankyo Group is dedic<strong>at</strong>ed to the cre<strong>at</strong>ion and supply of innov<strong>at</strong>ive pharmaceutical products to addr<strong>es</strong>s the diversified, unmet medical<br />
needs of p<strong>at</strong>ients in both m<strong>at</strong>ure and emerging markets. The company was cre<strong>at</strong>ed in 2005 through the merger of two traditional Japan<strong>es</strong>e<br />
enterpris<strong>es</strong>, Daiichi and Sankyo. With net sal<strong>es</strong> of more than €8.6 billion, Daiichi Sankyo is one of the world’s 20 leading pharmaceutical compani<strong>es</strong>.<br />
The company’s world headquarters are in Tokyo. Its European base is loc<strong>at</strong>ed in Munich. Daiichi Sankyo Europe has affili<strong>at</strong><strong>es</strong> in 12 European<br />
countri<strong>es</strong> in addition to a global manufacturing site loc<strong>at</strong>ed in Pfaffenhofen, Germany.
DSM<br />
Contact: Mr. Michael Janssen<br />
The Branch Pentapharm, since 2007 part of DSM, is a manufacturer of haemeostasis diagnostics:<br />
T<strong>es</strong>t kits e.g. Pefakit® APC-R Factor V Leiden, PiCT® (for UFH, LMWH and/or anti-FIIa and FXa drug monitoring), Reptilase Time, in-TDT® (for<br />
thrombin gener<strong>at</strong>ion), or OEM products.<br />
Reagents (from r<strong>es</strong>earch to bulk quantiti<strong>es</strong>) including customer manufacturing n: synthetic chromogenic, fluorogenic and amperogenic substr<strong>at</strong><strong>es</strong>,<br />
protease inhibitors and snake venom enzym<strong>es</strong>.<br />
Active pharmaceutical ingredients: aprotinin, peptid<strong>es</strong> and snake venom derived enzym<strong>es</strong> (B<strong>at</strong>roxobin, Haemocoagulase ) and synth<strong>es</strong>is of<br />
peptid<strong>es</strong> and small organic molecul<strong>es</strong>.<br />
INTRUMENTATION LABORATORY<br />
Instrument<strong>at</strong>ion Labor<strong>at</strong>ory (IL) is passion<strong>at</strong>e about delivering the most innov<strong>at</strong>ive solutions to addr<strong>es</strong>s a range of hemostasis t<strong>es</strong>ting needs.<br />
The advanced ACL family of systems brings complete autom<strong>at</strong>ion to the hemostasis lab—including the ACL TOP® Family of Hemostasis T<strong>es</strong>ting<br />
Systems, fe<strong>at</strong>uring the new ACL TOP 300 CTS; and, the ACL AcuStar®, the first fully autom<strong>at</strong>ed, chemilumin<strong>es</strong>cent analyzer for hemostasis<br />
specialty t<strong>es</strong>ting. Combined with the HemosIL line of reagents, a comprehensive panel of fully autom<strong>at</strong>ed assays, IL offers complete disease<br />
st<strong>at</strong>e management for the hemostasis lab.<br />
LEO PHARMA<br />
www.leo-pharma.com<br />
www.leo-pharma.fr<br />
Founded in 1908, LEO Pharma is an independent, r<strong>es</strong>earch-based pharmaceutical company based in Ballerup near Copenhagen. LEO Pharma is<br />
wholly owned by the LEO Found<strong>at</strong>ion. LEO Pharma develops, manufactur<strong>es</strong> and markets competitive drugs for thrombosis p<strong>at</strong>ients and in derm<strong>at</strong>ology<br />
in more than 100 countri<strong>es</strong>. LEO Pharma has offic<strong>es</strong> in 61 countri<strong>es</strong> and employs more than 5000 employe<strong>es</strong> worldwide.<br />
LFB GROUP<br />
The LFB group is a biopharmaceutical company th<strong>at</strong> develops, manufactur<strong>es</strong> and markets medicinal products for serious and often rare diseas<strong>es</strong>,<br />
in three major therapeutic areas: immunology, hemostasis and intensive care.<br />
Leader in France and 6th player worldwide in the field of plasma-derived medicinal products, the LFB Group also is a leading European company<br />
in the development of monoclonal antibodi<strong>es</strong> and new gener<strong>at</strong>ion proteins derived from biotechnologi<strong>es</strong>.<br />
With its strong r<strong>es</strong>earch activiti<strong>es</strong>, the LFB group is developing a growth str<strong>at</strong>egy to expand its busin<strong>es</strong>s activiti<strong>es</strong> by offering new therapeutic<br />
tre<strong>at</strong>ments and expanding into new intern<strong>at</strong>ional markets.
ROCHE<br />
www.roche.com<br />
Headquartered in Basel, Switzerland, Roche is a leader in r<strong>es</strong>earch-focused healthcare with combined strengths in pharmaceuticals and diagnostics.<br />
Roche is the world’s larg<strong>es</strong>t biotech company with truly differenti<strong>at</strong>ed medicin<strong>es</strong> in oncology, virology, inflamm<strong>at</strong>ion, metabolism and<br />
CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabet<strong>es</strong> management. Roche’s<br />
personalized healthcare str<strong>at</strong>egy aims <strong>at</strong> providing medicin<strong>es</strong> and diagnostic tools th<strong>at</strong> enable tangible improvements in the health, quality of<br />
life and survival of p<strong>at</strong>ients. In 2011, Roche had over 80,000 employe<strong>es</strong> worldwide and inv<strong>es</strong>ted over 8 billion Swiss francs in R&D. The Group<br />
posted sal<strong>es</strong> of 42.5 billion Swiss francs. Genentech, United St<strong>at</strong><strong>es</strong>, is a wholly owned member of the Roche Group. Roche has a majority stake<br />
in Chugai Pharmaceutical, Japan.<br />
ROVI<br />
Addr<strong>es</strong>s: Julian Camarillo, 35<br />
28037 Madrid (Spain)<br />
Telephone: 913756230 Fax: 913047881<br />
E-mail: rovi@rovi.<strong>es</strong><br />
www.rovi.<strong>es</strong><br />
ROVI is a fully-integr<strong>at</strong>ed, profitable Spanish specialty pharmaceutical company engaged in the r<strong>es</strong>earch, development, in-licensing, manufacturing<br />
and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products th<strong>at</strong> it markets in Spain<br />
through its specialized sal<strong>es</strong> force, calling on specialist physicians, hospitals and pharmaci<strong>es</strong>. ROVI’s portfolio of 30 principal marketed products<br />
is currently anchored by the internally-developed, second gener<strong>at</strong>ion low molecular weight heparin, Bemiparin which is also out-licensed and<br />
marketed in 50 countri<strong>es</strong> thanks to a network of partners. ROVI’s r<strong>es</strong>earch and development pipeline is focused primarily on addr<strong>es</strong>sing currently<br />
unmet medical needs by developing new Bemiparin indic<strong>at</strong>ions and the novel ISM (“in-situ microparticl<strong>es</strong>”) technology for injectable forms.<br />
SIEMENS<br />
Siemens Healthcare Diagnostics Products GmbH<br />
Contact: Michael Nöh<br />
Vice Pr<strong>es</strong>ident BU HHS Global Marketing<br />
Addr<strong>es</strong>s: Emil-von-Behring-Straße 76<br />
35041 Marburg (Germany)<br />
E-mail: michael.noeh@siemens.com<br />
www.siemens.com/healthcare<br />
Siemens Healthcare Diagnostics offers a comprehensive portfolio of performance-driven systems, unm<strong>at</strong>ched t<strong>es</strong>t menu, and inform<strong>at</strong>ion technology<br />
solutions for the in vitro diagnostic needs of hospital labs, reference labs, physician office labs, and point-of-care t<strong>es</strong>ting. We provide<br />
clinicians with the vital inform<strong>at</strong>ion they need for accur<strong>at</strong>e diagnosis, tre<strong>at</strong>ment, and monitoring of p<strong>at</strong>ients. Our diagnostic solutions — chemistry,<br />
immunoassay, autom<strong>at</strong>ion, hem<strong>at</strong>ology, hemostasis, microbiology, diabet<strong>es</strong>, urinalysis, blood gas, and molecular t<strong>es</strong>ting — are d<strong>es</strong>igned<br />
to streamline workflow, enhance oper<strong>at</strong>ional efficiency, and support improved p<strong>at</strong>ient care.<br />
STAGO<br />
Stago dedic<strong>at</strong><strong>es</strong> its r<strong>es</strong>earch and innov<strong>at</strong>ive skills to develop and improve the accuracy of the medical diagnostic. The firm formul<strong>at</strong><strong>es</strong>, manufactur<strong>es</strong><br />
and markets worldwide, a broad range of reagents and fully autom<strong>at</strong>ed systems for Haemostasis & Thrombosis.<br />
Thanks to its Haemostasis expertise, Stago is recognized and is in a position to cooper<strong>at</strong>e with the scientific community worldwide.
Sponsors<br />
GOLD SPONSOR<br />
SILVER SPONSOR<br />
BRONZE SPONSOR<br />
SPONSORS<br />
OFFICIAL JOURNAL<br />
STA ® -Liquid Anti-Xa<br />
The solution for UFH, LMWH and<br />
Fondaparinux monitoring<br />
Liquid form<strong>at</strong>, easy to use and reproducible<br />
Fully autom<strong>at</strong>ed assay<br />
Wide working range and increased on-board stability<br />
Dedic<strong>at</strong>ed and hybrid calibr<strong>at</strong>ions available<br />
Anti-Xa<br />
range<br />
Diagnostica Stago S.A.S<br />
RCS Nanterre B305 151 409<br />
9, rue d<strong>es</strong> Frèr<strong>es</strong> Chausson<br />
92600 Asnièr<strong>es</strong> sur Seine (France)<br />
Ph. +33 (0)1 46 88 20 20<br />
Fax +33 (0)1 47 91 08 91<br />
webmaster@stago.com<br />
www.stago.com<br />
www.epicea.com - Photo : Eric Meola/Gettyimag<strong>es</strong> - ©2011 Diagnostica Stago - All right r<strong>es</strong>erved - No contractual photos - 01/2012<br />
5<br />
130<br />
4<br />
VOLUME 130, ISSUE 4, PAGES 571–692<br />
THROMBOSIS RESEARCH<br />
OCTOBER 2012<br />
ELSEVIER<br />
VOLUME 130, ISSUE 4 OCTOBER 2012 ISSN 0049-3848<br />
THROMBOSIS<br />
RESEARCH<br />
Available online <strong>at</strong> www.sciencedirect.com<br />
MEDIA PARTNER<br />
Connecting the World of<br />
Biomedical Science<br />
Medical and Scientific Publishers<br />
TECHNICAL SECRETARIAT<br />
Tel.: +34 96 352 48 89<br />
Fax: +34 96 394 25 58<br />
www.geyseco.<strong>es</strong>
Change language